annual report despite extraordinarily challenging year people introduced new products advanced pipelines expanded businesses emerging markets way restoring mcneil consumer healthcare high levels quality compliance people expect johnson johnson companies expect meanwhile bringing forward innovations better health care people around world remain steeped tradition caring others driven values deeply rooted credo cover megan johnson enjoys simple everyday joys motherhood receives important health care information textbaby innovative mobile service expectant new mothers made possible national healthy mothers healthy babies coalition founding sponsor johnson johnson multiple partners textbaby symbolizes commitment caring health wellbeing mothers babies johnson johnson legacy years learn chairmans letter shareholders remembered year company william c weldon severely tested numerous fronts yet people continued chairman board directors chief executive officer hallmark work johnson johnson finding new ways care health wellbeing people around world maintaining investments future revenue earnings challenges fully expected particularly growth investments developing number related continuing global economic downturn loss exciting new products potential address patent exclusivity major pharmaceutical products significant unmet health care needs challenge expect painful worldwide sales billion decrease disappointing experience mcneil consumer healthcare percent operationally reflecting challenges noted well product recalls rd accounting week included results despite trying moments people introduced adjusted earnings billion increase percent new products advanced pipelines expanded businesses despite sales decline adjusted earnings per share increased emerging markets remain steeped tradition caring percent others driven values deeply rooted credo tough global economy maintained financial face nearterm business pressures enter strong discipline generated free cash flow approximately foundation achieve longterm sustainable growth billion held aaa credit rating also executed billion debt offering lowest interest rate longterm results corporate debt history continued deliver earnings growth many oneyear decline total shareholder return businesses performing well light macroeconomic half percent longer time frames continue conditions several factors impacted health care industry compare favorably stock indices beating major sector general johnson johnson medical devices consumer performance benchmarks threeyear year basis businesses felt effects continued economic slowdown oneyear decline shareholder return disappointing health care anticipate continuing feel effects reflects uncertainty around health care reform costs associated us health care reform hampered many sector impact consumer implemented early year addition faced product recalls lost sales remediation costs resulting consumer overthecounter product recalls well generic competition mcneil consumer healthc pharmaceuticals business people dedicate providing trusted despite headwinds continued grow earnings brands highquality products help others around world net sales diluted earnings per share dividends paid per share billions dollars dollars dollars chairmans letter thus experience mcneil consumer healthcare recalls accomplishments reflect strength model difficult us important disappointed growth enablers customers trust confidence johnson johnson new products introduced innovative products across products fundamental everything even though businesses saw strong growth recently introduced millions customers remain supportive work assure products include consumer products address quality restore consumer brands market trust emerging health care needs johnsons natural confidence truly tested baby products listerine zero mouthwash past year visited many manufacturing locations medical devices diagnostics mdd segment around world assure people dedicated launched new products example new giving customers highestquality products enseal tissuesealing device large vessel sealing open compromises whatsoever responsibility learn surgery introduced us strengthening energy happened address problems root causes ensure surgical instrument portfolio pharmaceuticals saw highestquality products reach customers growth key innovations approved nucynta hard workand subsequent resultswill help earn tapentadol pain stelara ustekinumab back trust respect simponi golimumab immunology invega way restoring mcneil consumer healthcare sustenna paliperidone palmitate schizophrenia high levels quality compliance people expect consistent flow new products based johnson johnson companies expect scientific innovation approximately quarter part commitment accelerated imple johnson johnson sales last year came new products mentation organizational changes supply chain introduced past five years approximately percent manufacturing quality compliance areas began sales products global early also undertook thorough review market share positions operated manufacturing plants examined detail historical production records mcneil consumer healthcare leading product pipelines across businesses products sold us produced mcneils internal invested nearly billion research development manufacturing network advance newest technologies pipeline compounds completed internal review pharmaceuticals pipeline recognized among continue conduct reviews external sites manufacture best industry mcneil products reviews reveal issues rivaroxaban anticoagulant filed hesitate take whatever steps needed including us prevention stroke patients atrial market action ensure products meet fibrilation condition lead major physical worldclass quality standards steps behaviorial impairments death company also taken comprehensive action plan submitted responded fda complete response letter review us food drug administration fda constitute rivaroxaban filing preventing deep vein thrombosis uncompromising effort ensure high quality mcneil pulmonary embolism following total knee hip actions help us assure moving forward replacement surgery abiraterone acetate investigational products marketplace live standards compound treatment metastatic advanced prostate expectations consumers products coming cancer last years acquisition cougar biotechnology johnson johnson granted priority review us accepted time focused returning recalled accelerated assessment europe telaprevir products marketplace began shipping small hepatitis c undertreated global infectious disease amount product fourth quarter alternate also accepted accelerated assessment europe supply remaining key products ramp latter additionally filed tmc hiv us half appropriate time invest market europe support overthecounter brands also mdd fibrin pad revolutionary hemostasis introducing product packaging innovations number product combines two biomaterials two biologics products especially young children stop bleeding surgical procedures filed regula tory approval fda highlights even faced challenges throughout remained targeted acquisitions believe organic unwavering company source collaborative approach innovation addition enduring strength fundamental commitment credo internal research development programs create operating model served us well decades partnerships licensing make targeted acquisitions operating model includes commitment either add capability gain asset broadly based human health care decentralized management drive value acquired micrus endovascular approach keeps people close customers managing long term focus people values focus four nucynta licensed grnenthal gmbh growth enablersproducts pipelines global presence rivaroxaban codeveloped bayer healthcare peoplethat support model enable accelerated growth telaprevir developed collaboration vertex pharmaceuticals inc johnson johnson annual reportglobal developer manufacturer minimally invasive devices hemorrhagic ischemic stroke february source enduring strength johnson johnson completed tender offer fundamental commitment crucell nv develops vaccines infectious diseases addition strategic acquisitions collaborate credo partner companies academic institutions pursuing exciting discoveries enhance operating model global development capabilities served us well decades growth emerging markets continued strong progress emerging markets sales growing percent operationally brazil russia india china continue maximizing research development centers regions develop medical devices pharmaceuticals consumer products based insights local markets broadly based vast growing network medical surgical human health institutes around world train educate doctors nurses use products rapid economic growth emerging markets expanding product managed decentralized offerings meet unique needs mass market long term approach comprising billions people gaining greater degree health care coverage opportunity may reflect affordable people products products focused diseases values common emerging markets developed markets offerings include marketappropriate sutures consumer products staplers blood glucose meters knee replacements local regional pharmaceuticals objective superior outcomes patients may access technologies products experienced operational sales decline percent excluding talented people look toward future top impact generic competition health care reform priority johnson johnson continued development pharmaceutical sales would increased nearly percent leadership team wellpositioned sustainable growth operationally end announced organizational changes continued make significant investments expand designed longterm succession plans assure presence emerging markets grew double talented experienced leaders levels digit rates well new therapeutic areas like vaccines organization joining part expanded office alzheimers disease leader us chairman alex gorsky previously worldwide chairman immunology market three significant brands medical devices diagnostics sheri mccoy previously flagship product remicade infliximab treatment worldwide chairman pharmaceuticals number immunemediated inflammatory diseases additions senior leadership team grew percent operationally newer products stelara direct reflection strength depth diversity ustekinumab simponi golimumab continued talent pipeline committed giving people increasing market share generated combined opportunities work across various business groups million sales year remicade stelara geographies continue invest ever simponi contributed percent operational growth people objective simple develop employees immunology franchise skills judgment integrity carry longacting antipsychotics grew percent johnson johnson legacy operationally risperdal consta risperidone long people products pipelines footprints acting injection atypical antipsychotic administered global markets sustain longterm growth every two weeks treatment schizophrenia continuous focus addressing unmet needs invest maintenance bipolar disorder grew percent operationally technologies potential significantly improve invega sustenna paliperidone palmitate health care treatment schizophrenia continued increase us market share contributing expanding market leadership pharmaceuticals hiv area prezista darunavir intelence pharmaceuticals segment focuses meeting important etravirine grew sales operationally percent patient needs sales billion saw rapid growth percent respectively achieving together billion recently launched products year segment sales first time providing access markets chairmans letter significant need medical devices diagnostics oncology velcade bortezomib multiple myeloma segment sales grew percent operationally eclipsing billion sales sales major franchise billions dollars outside us first time sales billion ende ot h suic ro gn e r addition continue pursue line extensions sales change submitted applications several major line extensions total operationmal among remicade simponi continue build strength immunology franchise ethicon orthoclinical next three years expect file compounds diagnostics address critical medical needs including alzheimers disease diabetes conditions growing prevalence population ages five compounds currently registration several planned coming years portfolio ranks among diabetes vision leaders industry pipeline meets unmet needs care care features many true innovations designed change treatment paradigm patients de pu co rd ed mca edl ce av l dic ee vs ca en sd ni da dgn iao gs nt oi sc ts ics mdd franchises comprise worlds largest medical technology business sales billion increase approximately percent pharmaceutical segment sales operationally despite economic slowdown led sales major product billions dollars decline surgical procedures pricing pressures across sales billion remicade business achieved growth six seven franchises sales change well regions oo pt ea rl io n l r ci op n e srm td aa rl mdd businesses advanced strong pipeline h completed integrated several acquisitions aggressively procrit p ep x topamax expanded emerging markets segment maintained improved market share majority largest product levaquin velcade platforms despite intense competition floxin example ethicon franchise grew percent operationally based strong suite surgical products concerta well recent acquisitions new markets like aesthetics ear nose throat surgery ethicon endosurgery franchise grew percent operationally doubledigit growth advanced aciphex pariet sterilization products energy products major contributors vision care franchise operational sales growth percent based core acuvue brand contact lens continued launch day acuvue trueye contact lenses new markets ortho clinical diagnostics franchise grew percent operationally continued growth consumer segment sales vitros analyzers sales major franchise billions dollars pharmao ct ec u ticals sales billion nu tr io nals depuy franchise increased operational sales percent sales change based strength orthopaedic reconstruction sports total medicine neurological businesses diabetes care increased operaticonal operational sales percent introduction number n w ho em ale tn hs new onetouch products around world meanwhile u sales cordis franchise continued decline due competi tion drugeluting stents partially offset strong e r growth electrophysiology products biosense webster oral care wound business grew nearly percent operationally year care ot h e r consumer consumer sales billion decline approximately percent operationally sales impacted mcneil recalls well general economic slowdown greater consumer baby care skin care sensitivity spending reflected broad move towards store velcade trademark millennium pharmaceuticals inc operational excludes impact currency johnson johnson annual reportbrands smaller sizes certain markets unwavering fiveyear commitment united despite headwinds saw positive nations renewed efforts advance commitment momentum emerging markets millennium development goals reducing sales grew double digits principles embodied mortality women children operational sales decreased commitment aims help many credo consumer franchises however saw million women year next growth many product lines including appreciation five years reaching countries includes dabao skin care products nicorette initiatives mobile health elements johnsons aveeno le petit information expectant mothers safe marseillais sciencebased operating model birth programs million doses innovations expansion emerging annually mebendazole treatment strong today markets continued drive strong results intestinal worms children also introduced new product time addition commitment innovations line extensions iconic support nearly philanthropic history brands johnsons natural programs countries listerine zero precise working saving improving lives makers tylenol zyrtec liquid women children also focus gels cytomimic technology building skills people serve several new skin care products community health needs well consumer business continues distinguish preventing diseases reducing stigma disability sciencebased innovations proprietary technologies underserved communities recommendations health care professionals billion people around world count consumer products c ommitment ou families commit shareholders enter johnson johnson wellpositioned future growth enduring trength restore quality confidence products continue challenges within context introduce differentiated new products advance important th anniversary reminded ever unmet needs human health wellbeing continue heritage unwavering commitment principles embodied building advancing pipelines fuel longterm success credo appreciation elements well continue expanding new health care categories operating model strong today time history emerging markets offer unprecedented opportunities perfect make mistakes touch people around world better care hold accountable correct important never lose sight accountability inherent credo tenets demand credo operating model people enduring special level responsibility first patients customers sources success deeply committed people employees communities shareholders use products employees communities credo remains north star live work loyal shareholders another enduring strength character people johnson johnson despite diverse businesses united extraordinary bonda commitment caring one person time touching worldoriginating credo values quiet sense purpose focused around lives william c weldon affect families children touch professionals chairman board directors chief executive officer support health products pipeline global presence make us march strong company people credo set us apart c ommitment women children businesses diversified expanded globally johnson johnson remains true foundation company caring health wellbeing mothers children heritage unlike company especially privileged touch mothers intimate moments newborn child bond forged deep emotional trustone builds special connection people also magnifies commitment help ensure mothers children wherever may live enjoy good excludes special items health care f ree cash flow defined operating cash flow less capital spending consistent legacy johnson johnson responded see reconciliation nongaap financial measures chairmans letter pharmaceuticals hope patients infectious diseases researcher working hepatitis c clinical trials around world brian woodfall md aware challenges patients face many endure yearlong drug treatments undergo liver transplant even die complications related bloodborne virus many people dont tolerate review us food drug admin current drugs well feel sick istration european medicines says woodfall vice president global agency tmc evaluated globally clinical development tibotec several large phase iii trials pharmaceuticals end drugs potentially decrease treatment many people arent cured patients time away work family current standard treatment may get back improved health successful less percent faster woodfall says research patients prevalent form driven intense commitment save hepatitis c alternative lives improve patients health medicines dont respond daytoday basis million people worldwide infected hepatitis c rd expands infectious diseases million new cases year hepatitis c medicines among according world health treatments infectious diseases organization common cause vaccines therapeutic area developing cirrhosis liver liver cancer address high unmet medical needs globally liver transplants worldwide already world leader hiv medicines franchise developing new treatments innovative treatments aim tuberculosis tb hiv part development infectious diseases cure patients nered crucell nv develop adds greater impact meet critical need tibotec influenza treatment vaccine february improving human health globally pharmaceuticals developing two new johnson johnson completed expansion prevention build treatments hepatitis c drugs tender offer crucell develops vaccines pipeline particularly telaprevir tmc vaccines infectious diseases world emerging markets potential cure significantly people wide result crucell operate currently available therapies center vaccines within breakthrough treatments halve patients treatment time pharmaceuticals group one worlds oldest deadly months six telaprevir named one developing effective infectious diseases tuberculosis kills top medical innovations treatments infectious diseases million people year company cleveland clinic undergoing improve lives millions people researchers work tb ground around world says paul stoffels md breaking first time telaprevir developed collaboration worldwide chairman pharmaceuticals years new class drugs vertex pharmaceuticals inc tmc developed collaboration medivir ab addition growing research potentially effective tb johnson johnson annual reportdiscovered clinical trials dr stoffels hope create committed research treatment tmc initially target lifesaving drug tmc passion scientific research ramon increasing number patients two new hepatitis c medicines polo left brian woodfall working failed tuberculosis therapies due protease inhibitors also develop telaprevir hepatitis c drug resistance tibotec partnered breakthrough treatments may offer like others tibotec belgium theyre nonprofit global alliance new hope patients failed prior driven knowledge efforts tuberculosis drug development drug therapies well intended potential improve conduct studies tmc patients treated hepatitis c health help people survive patients undergoing tb treatment first time drugs would first time administered combination patients around world addition new hiv drug tmc existing standard treatment dr stoffels says highest thing rilpivirine undergoing regulatory goal use science human lifetime review may add already strong understanding infectious diseases passion making difference lives hiv portfolio generally safe help people survive improve health patients around world welltolerated clinical trials says make significant difference lives drives us johnson johnson annual report reducing risk heart disease rivaroxaban promising experimental medicine may soon become new alternative warfarin reducing risk unwanted blood clots johnson johnson pharmaceutical research development llc jjprd recently submitted new drug application us food drug administration fda seeking approval use rivaroxaban prevent strokes patients common heart rhythm disorderatrial fibrillation results rocket af trial comparing rivaroxaban warfarin widely used challengingtomanage drug advancing cancer care fighting cancer clinical trial presented participant richard pflaum american heart association wife kathy hope hell benefit annual meeting advances treating cancer studys outcome suggests rivaroxaban living cancer increase disrupt surrounding tumor potential protect need positive attitude says abiraterone acetate microenvironment helps million americans atrial yearold richard pflaum received marketing authoriza cancer thrive using fibrillation stroke bath england tion investigational biomarkers improve patient devastating complica need able take use based positive outcomes tions according peter sort action richard results completed abiraterone acetate acts dibattiste md vice president participating ongoing phase iii study marketing blocking synthesis cardiovascular development clinical study abiraterone applications filed hormones produced jjprd rocket af acetate promising regulatory authorities body including produced seventh successful phase iii investigational medicine us europe december prostate cancer tissue fuel trial ongoing rivarox treatment metastatic additional filings growth according william aban development program advanced prostate cancer planned hait md phd global jjprd also globally prostate cancer abiraterone acetate therapeutic area head expects learn fda second frequently oncology franchise devel oncology believe whether rivaroxaban diagnosed cancer men oping strategies hopes abiraterone acetate impor approved prevention fifth common cancer one day help prevent cure tant medical advance blood clots following total overall certain types prostate look forward devel knee total hip replacement new cases prostate cancer cancers researchers oping additional therapies surgeries diagnosed working handinhand oncology patients help men died todays top oncology experts save lives people around rivaroxaban codeveloped disease percent testing compounds world says bayer healthcare johnson johnson annual reportpursuing another treatment new treatment areas targeting simponi golimumab june centocor ortho solutions approved treat biotech inc acquired respivert diabetes ment rheumatoid arthritis ltd drug discovery company immunology psoriatic arthritis focused developing inhaled ankylosing spondylitis smallmolecule therapies approved approximately treatment pulmonary countries two additional diseases applications filed seek sue dillon phd global elizabeth menduke lives expand us label therapeutic area head worldwide million outside los angeles include inhibition immunology explains people live diabetes owns business progression structural acquisition strengthens almost equal entire result psoriasis damage treatment capabilities build us population scaly red rheumatoid arthritis pipeline novel oral diabetes farreaching patches psoriatic arthritis biologic therapies complex disease says martin percent body remicade infliximab focused areas fitchet md head treatment stelara treatment fda asthma chronic obstructive cardiovascular ustekinumab plaque approvals also received addi pulmonary disease idiopathic metabolism therapeutic area psoriasis elizabeth says tional marketing approvals pulmonary fibrosis sarcoidosis working develop excited including several japan lupus says dillon new treatment options clearer skin remicade available continue make help better stelara treatment countries difference patients lives manage disease approved moderate incremental growth potential limit severe plaque psoriasis existing products clearer skin psoriasis progression available important strategy kept elizabeth menduke large clinical countries result immunology therapeutic area feeling best development program additional marketing also expanded research clearer skin treatment canagliflozin new approvals development capabilities stelara plaque psoriasis collaborations supported companys commitment build portfolio diabetes treatments canagliflozin investigational oral selective sodiumglucose transporter sglt inhibitor studied patients treatment type diabetes phase iii clinical trial program involves patients new collaboration metabolex inc focuses discovering developing commercializing new treatment options people type diabetes obesity agreement entered diamyd medical ab support development pharmaceuti cals targeting autoimmune diabetes complica tions particular treatment prevention type diabetes canagliflozin developed collaboration mitsubishi tanabe pharma corporation johnson johnson annual report emerging markets local insights inspire new products urgeon zhao zhongliang serves farming johnson johnson also entered pharmaceutical research community chinas hebei province recently partnerships connect biotech worked ethicon endosurgery franchise medical academic communities global research centers one develop new marketappropriate surgical partnership cancer research formed stapler meet needs patients like tianjin medical university cancer hospital china november specialized surgical staples often creating possibilities governments research collaboration used connect tissue certain deliver higher standard care many tsinghua university china surgeries theyre credited quicker people reforms along janssen pharmaceutica nv recovery times suturing hand rise middle class expectations announced fiveyear strategic emerging markets often costs better quality life providing partnership aims accelerate discovery much use specialized equipment johnson johnson enormous research foster new therapeutic designed developed markets dr zhao opportunity address previously approaches infectious diseases excited new surgical tool underserved market area significant unmet medical need could mean patients mass markets addressed one feel contribute patients receive better different business model positively public health goals health care lower cost certainly focused bringing appropriate port china says kim taylor company grateful says patients dont folio technology products smaller group chairman pharmaceuticals carry psychological weight financial rural health care settings asia pacific burden recovery complete matching specific range procedures johnson johnson health care company passionate offered approach led established firstofitskind latephase meeting unmet needs development highquality affordable chemical entity facility analytical hundreds millions patients products provide superior outcomes pharmaceutical development center johnson johnson needs challenge patients would otherwise mumbai india center play key innovation capability develop solutions access technology role addressing major global health appropriate afford care challenges many also face able end johnson johnson passion innovation mumbai region strategically basing research develop vision source innovation consumer sector ment rd centers emerging markets emerging markets address emerging market innovation center develop medical devices pharma unique needs asia pacific patients opened shanghai built ceutical consumer products based says michael del prado company group consumer closeness bonding insights available local markets chairman medical devices diagnostics program integral part emerging asia pacific might include devices market product design development emerging market needs specific disease states prevalent meet needs china asia pacific region home asia simplified smaller instruments happy johnson johnson billion people almost percent multiuse disposable products focused making new technologies worlds population economical product range better health care accessible affluent societies japan australia rural health centers lowerincome patients says dr zhao coastal china metropolitan india june medical devices results better outcomes access innovative products diagnostics rd center open fewer complications really improving services large segment population suzhou china focused market lives patients unable access afford much appropriate innovation fastgrowing beyond basic level health care emerging markets functions support improving lives surgeon zhao innovation also based campus zhongliang happy part making recent health care reforms china including new product development new technologies better health care india spurred continuing marketing clinical research regulatory accessible patients like economic growth countries quality assurance operations farming community serves johnson johnson annual reportconsumer natural choices ara snow indianapolisbased tv host elevates heritage brand greenliving expert gives baby rubadubdub traditional natural johnsons products meet cleaning johnsons natural headtotoe expectations purity mildness foaming baby wash hands daughter dad gentleness inherent heritage towel snuggle especially baby products business holland says giving moms choice less says sara fantastic product line includes three baby june johnson johnson holland says natural ingredients two kids products johnsons consumer companies inc launched essential oils irritating natural baby lotion johnsons johnsons natural baby line allergenic natural headtotoe foaming north america bringing new affordable johnsons ultimately developed baby wash johnsons natural natural baby products moms mass standard babies called best baby shampoo johnsons natural retail brand developed baby naturals standard led kids shampoo conditioner response growing number formulation percent natural body wash johnsons parents like sara environmen washes percent natural natural kids hand face tally conscious also want natural lotions using plant fruitderived foaming wash products babies five products ingredients contains sara snow meanwhile especially least percent natural derived tears formula first percent appreciates prices lower fruits plants naturally derived fragrance allerfree specialty natural brands growing number consumers free known allergens products available everywhere world want natural irritating essential oils mass retail really like solution says patrick mutchler company addition johnsons natural affordable anyone get group chairman global leader packaging thoughtful sustainability hands says sara baby care responsibility meet considerations plastic bottles contain fan products different needs different mothers colorant use percent post became spokeswoman go consumer recycled content feature product long natural sustainable silkscreened graphics rather labels trusted brand like johnsons johnsons poured years reducing packaging weight waste really research people experience plus science rigorous product line honored find real sense security testing expertise developing earthwards designation comfort natural line one challenge defining johnson johnson gives products mild gentle natural many demonstrate significant improvements sara snow continues organizations formulated standards environmental footprint environmentally conscious criteria dont address unique johnsons natural forged choices child like using needs babies partnership national wildlife johnsons natural baby products natural products mild federation encourage childrens product line recognized enough babys skin says exploration natural surroundings earthwards designation jean holland worldwide franchise rd forged partnership director example babys skin trademark national wildlife national wildlife federation thinner sensitive adults federation please visit wwwnwforg learn wwwjohnsonsbabycom johnson johnson annual reportjohnson johnson annual report guarding tooth erosion one bodys strongest substances tooth enamel plays vital role protecting sensitive inner tooth daily wear tear yet todays lifestyle eating drinking goparticularly acidic food drinkenamel erosion common uk percent dentists report seeing patients acid erosion weekly basis adults experience cavities caused tooth decay rinsing listerine total care enamel guard unique blend listerine essential oils enhanced fluoride helps remineralize reharden tooth enamel product successfully strengthening trust treating fever doctors launched uk august areas china expanding pediatricians parents able give children like yun europe markets han yang pediatric motrin globally listerine brand children especially prevalent significant driver smaller communities oral care business pediatric motrin pediatric fever category pediatricians nationwide listerine total care became available town larger cities since widely embraced guide products including lv xiang fevers education awareness motrin gained trust listerine total care children like yun han yang campaign successfully well trust parents enamel guard accounted part china brought pediatrician like hai yan li half commonly treated recommended antifever shanghai johnson johnson brands total sales injection mom solution children across pharmaceuticals china continued success hai yan li says able country including medical association also listerine mouthwash go local clinic oral smaller cities towns like collaborate motrin pediatric europe based deep treatment easier every lv xiang world window launched understanding consumer one shes comforted knowing campaign uses firstof improve pediatric care needs met motrin offers safe itskind fever treatment providing continuous education innovative products says effective relief fevers guide developed shanghai pediatricians neil dickenson oral care pediatric motrin johnson johnson pediatricians franchise director europe manufactured china pharmaceuticals ltd around china participated middle east africa since collaboration china satellite symposia latest listerine total care introduced quickly medical association address advances pediatric academic key focus driving became market leader incorrect treatments fever knowledge research growth across region johnson johnson annual reportprotecting research technology integral success connecting center jos dos campos roc minesol today skin matches sun protection dermatologistrecom innovation consumer mended sunscreen brand lifestyles brazils mostly brazil fact one two consumers tropical climate skin care sunscreens sold country general become johnson johnson online important brazilian consumer brand little two decades consumers strong educational ago johnson johnson aware need sunscreen material offered industrial ltda brazil dermatologists brazilians two launched campaign raise recommending sunscreen decades one main awareness harmful ages says maria eduarda reasons consumers making effects tanning without kertesz vice president informed choice use sun protection took primary beauty latin america protection says kertesz role educating brazilians weve responded trend weve played role making importance using products combine sun protection part daily online home shopping sunscreen sundown skin care benefits routine people brazil specialty channels first ever sunscreen antiaging sun showing tremendous growth wearing sun protection introduced brazil protection making easier globally premium skin brazilians mariana pedro since company consumers use care beauty category enjoy time beach continued educate people dermatologists recommend include tv mobile mom knows daily sun protection encourage daily application application sunscreen helps enabled shopping branded bring forward meaningful sun protection protect suns stores doortodoor sales products dermatologists damaging rays advantages specialty channels offer including discounts fast delivery make attractive price sensitive loyal customers early adopters consumer business moving alternate channels building organizational capabilities support strategy korean skin care market one example neutrogena brand saw doubledigit growth korea engaging consumers content solutions acne clearskin website products specifically designed sale online direct links purchase brands main revenue drivers strategic alliances top online retailers helped make clean clear teen skin care brand major online channels korea aveeno baby site become hub sharing aveeno product experi ence well viral marketing efforts like korea contributed growth outside us johnson johnson annual report medical devices dia gnostics reaching world uring total hip knee surgery china product offerings expanded meet unique needs extremely challenging control bleeding says mass market comprises hundreds surgeon marco dimporzano md bleeding millions people access site often difficult reach difficult degree health care mdd businesses launched number control bleeding traditional surgical techniques marketappropriate products china gaetano pini hospital milan italy taken best technology leveraged recently ethicon endosurgery inc dr dimporzano access new global network johnson johnson introduced advant linear hemostasis product ethicon inc companies provided strategic plan stapler hcs disposable used stop bleeding evicel executed local teams curved circular stapler fibrin sealant human thawed doctors access leading technology designed specific asian markets ready ondemand help surgeons meet make meaningful differences onetouch ultravue blood critical bleeding challenges patients glucose meter lifescan inc evicel fibrin sealant approved evicel sealant successfully launched japan general hemostasis surgery biologic medical device product mid popular meter used surgical setting knowledge experience launching meter introduced control bleeding standard surgical pharmaceuticals well medical devices china diabetes quickly techniques ineffective impractical needed expand many markets becoming epidemic recent data human plasmabased biologics quickly markets like turkey indicates one people china evicel sealant allow work greece medical devices diagnostics disease independently patients clotting mdd teams reached accelerate progress factors creating simple solution counterparts pharmaceuticals local emerging markets research complex bleeding problems expertise best way manage development done outside us often surgical success depends complexity italy provinces see story ability quickly effectively control distinct regulatory bodies bleeding surgical site evicel specific requirements patient needs drive efforts sealant become critical tool assist strategy provide local efforts develop marketappropriate surgeons ensuring bleeding leadership comprehensive cross products quickly globalize new surgery doesnt become life functional tools says ron horton group existing products rely ability threatening product director ethicon inc led leverage capabilities throughout availability powerful topical evicel sealant globalization efforts johnson johnson result reaching hemostatic product extremely approach used scalable adaptable world products important says dr dimporzano using business units could prove make difference product like evicel together beneficial teams mdd excites biosurgicals team minimally invasive surgical approach pharmaceutical segments work weve achieved important market lead improved outcomes patients achieve global business goals presence evicel paving way evicel sealant first product products developing says omrix biopharmaceuticals inc globalization drives business dan wildman worldwide president ethicon taking global markets ability quickly globalize products ethicon inc responsible ethicon ethicon acquired omrix one way mdd business segment biosurgery unit meeting significant evicel sealant available one capitalizing globalization another needs surgeons meeting vital country end developing marketappropriate needs patients countries end products countries including italy today global mdd market worth surgical success dr marco launched october approximately billion dimporzano completes hip great example weve percent outside united knee replacements year used scale quickly globalize states markets growing says adjunctive hemostatic products important products says randy hubbell slightly faster rate emerging markets like evicel sealant combined worldwide vice president ethicon growing still fastertwo three minimally invasive approach proce biosurgery unit evicel weve times rate overall market dures may improve outcomes johnson johnson annual reportstopping approximately million hospital england local world episodes health care emergency hospital used deadly associated infections hais glosair systems help without year causing million reduce hai rates weve infections extra days hospital stay achieved one lowest limits deaths another conse mrsa rates national quence hais place significant health system since adding people cost pressure hospitals glosair infection glosair helps reduce prevention practices says diabetes risk hais course andrews nearly years ago become new standard care since acquiring gloster johnson johnson pioneered studies show safe europe asp readytouse surgical userfriendly technologya leveraged ability take diabetes global epidemic dressings helped keep hydrogen peroxide drymist glosair markets thats increasing pathogens infecting systemis effective global rollout began alarming rate one wounds advanced method disinfecting health launches throughout europe biggest challenges people sterilization products asp care settings following plans launch diabetes face keeping division ethicon inc cleaning sole reliance us blood glucose levels range pioneering reduction manual application tradi says kenneth moritsugu md pathogens health care tional disinfectants infection prevention vice president lifescan inc settings glosair area machines helped paul andrews colleague better control lead disinfection products us maintain good standard carrole white use glosair fewer longterm complica world health cleaning manage safe system help reduce tions ultimately lower organization estimates patient environment says health careassociated health care costs europe million paul andrews housekeeping infections dorset county thats diabetes patients affected manager dorset county hospital england care franchise remains dedi cated creating world without limits people diabetes delivering innovative products tools easy health care providers teach give patients helpful information lifescan began global rollout onetouch verio blood glucose monitoring system accurate easytouse system requires coding filters many common interferences reducing chance error system testmarketed netherlands patients insulin therapy launched australia europe markets follow also animas corporation leader insulin pump systems partnered juvenile diabetes research foundation develop firstgeneration partially automated glucose management system step toward goal revolutionizing treatment type diabetes johnson johnson annual reportnew strength stroke treatment million people worldwide suffer stroke year many onethird die according world health organization often treatment interven tions prevent stroke require physicians use special devices gain access brain two companies neurointerventional ists rely devices come together create one broadest portfolios one deepest pipelines neurovascular industry september johnson johnson acquired micrus endovascular unlocking dimensions optimistic outlook corporation global devel heart rhythm caused oper manufacturer human heart fatigue worry minimally invasive devices volunteer fireman thomas hemorrhagic caused buehler since afib bleeding ischemic ablation procedure caused blockage stroke says anxiety stress significant unmet thomas buehler round life small felt gone needs treatment lake ill hopeful common form neurovascular disease says kicked atrial fibrillation afib irregular heartbeat afib affects dr natale carto p laxmin laxminarain life hasnt recur million people system shows real worldwide president codman rence since afib ablation worldwide leading time exactly shurtleff micrus procedure year ago cause stroke among people allows create endovascular codman electrophysiologist age treatment called virtual geometry heart neurovascular develop andrea natale md facc afib ablation passes energy procedure innovative complementary fhrs shares optimism thin wire catheter accurately products technologies although never tell placed inside heart seven years prior treating cerebral aneurysms patient forget disrupt specific tissue identified procedure tom suffered lead stroke completely says dr natale trigger carto frequent afib flareups hope bringing general people system advanced lasted anywhere companies together says well beyond one year imaging technology two eight hours laxminarain fuel chance recurrence later biosense webster inc helps depressing says recalling rapid meaningful electrophysiologists perform extreme fatigue came innovation thermocool navigation afib ablation high degree recently retired catheters approved drug improves therapeutic options accuracy loves taking long walks refractory recurrent symptomatic access care fine line enjoying living life paroxysmal atrial fibrillation ultimately makes difference right thing anxiety stress used carto systems treatment excluding navistar rmt patient taking gone life changed debilitating condition thermocool catheter chance complication says completely johnson johnson annual report johnson johnson supply chain pathway patients heres pride also big sense drugs combination products standardizing processes responsibility says quality systems providing greater ray hanley operations development oversight area reduce coordinator depuy ireland complexity risk area quality says kathy wengel chief knees leave every day implanted patients quality officer jjsc around world nurturing growth tomorrow johnson johnson supply chain jjsc procurement customer logistics addition improving quality helps coordinate path health services asset allocationwhile compliance new model designed care products take reach people maintaining critical decentralization enable growth improve efficiency doctors nurses patients mothers sector operating companies one effectiveness crosssector fathers caregivers meet proven strategies johnson johnson collaborationkey bringing forth needs ultimately new approach health care technologies draw processing orders others supply chain improve experience expertise one business work genuinely feel important customers business segmentwill flourish manufacturing get highquality product johnson johnson companies quality experts various ought says elaine eager generating incremental value business units opportunities international supply group team leader businesses says shetty combine talents depuy ireland personally campus ireland one example transported knee implant hospital due enabling performance today six manufacturing facilities urgent patient need simply organizational design jjsc ireland across medical devices moving product one place includes new operating model quality diagnostics pharmaceutical anotherits transforming lives compliance qc new structure businesses close proximity worldwide jjsc includes network supply chain strategy project facilities enables companies manufacturing sites external management crosssector collaboration work collaboratively range manufacturers distribution centers new enterprise model helps projects facilitating transfer approximately associates facilitate already playing recovery employees sites specific supply chain organization large plans related manufacturing issues projects career development part company plays experienced mcneil consumer promotion opportunities campus vital role ability meet needs healthcare leaders ireland also working toward customers says ajit shetty phd mcneil situation us creation shared stateoftheart corporate vice president responsible rethinking business continuity planning manufacturing facility convergent jjsc deployed new supply chain utilize plants partner medical technology products operating model enable growth suppliers says robert salerno vice journey coordinate drive quality compliance help us president supply chain strategy supply chain organizations way run efficiently effectively project management jjsc rather shetty says operating model serve patients consumers worldwide plan around one operating unit potential benefit serve approach manufacturing driving quality efficiency effectiveness new holistic model johnson johnson vantage point touchingand formation enterprise supply new supply chain model transforminglives years come chain operating model announced able leverage assets best practices january objectives new systems technologies offering putting patients first organization enable growth drive supply chain leaders professional close collaboration colleagues quality compliance improve costs development opportunities across throughout supply chain allows provide professional development companies gain holistic appreciation steps people new operating model also activities patient created business leaders create single framework qc across says ray hanley cork ireland three sectors model coordinate companies inclusive common quality insights used decisionmaking essential supply chain functionslike standards product types devices put patients first johnson johnson annual reportjohnson johnson years caring h aving heard joseph lister speak robert wood johnson inspired start company manufacture first massproduced sterile surgical dressings sutures according listers methods helping make surgery safer save lives brothers james wood johnson edward mead johnson founded johnson johnson company come known caring caring inspires people companies added new miri seiberg phd distinguished johnson johnson advance health companies came great scientists research fellow skin biology wellbeing johnson dr philip levine studied human blood group johnson johnson consumer brothers embrace research discovered many subgroups companies inc combine science bring forward innovative ideas blood typing work led knowledge technology products services work development rhogam first innovative ideas create better products partners health care touch lives rho immunoglobulin product treat better serve customers throughout world hemolytic disease newborn seiberg recipient meeting unmet needs health care product helped save lives discovery development one important mandates countless babies dr paul janssen totalsoy skin care platform foster innovation internally belgian scientist one th technology external collaborations says centurys innovative inspiring scientists make new discoveries garry neil md corporate vice pharmaceutical researchers discovered gain deeper understanding president corporate office science haloperidol led teams credited human body doors open technology throughout business discovering medicines develop new products says shawn stad segments talented driven promise new innovations inspires staff engineer depuy inc scientists whose work heart johnson johnson scientists today recipient role developing product innovations continue bring miri seiberg shawn stad mariepierre viper minimally invasive spine forward weve done years de bthune among select scientists system always need dr frederick barnett kilmer share distinction received medical intervention companys first scientific director johnson medal research always value better chief publicity officer development outstanding science mariepierre de bthune phd dr kilmer spread knowledge antiseptic technology relating contributions vice president external innovation methods treating wounds furthered specific product process named tibotec bvba receiving medal shows scientific direction company late general robert wood johnson ultimately work makes helped earn trust expanding authored credo difference patients highest product lines among physicians prestigious award research recognition get patients patients tenure saw many pioneering development corporation thank us drugs says de bthune firsts including steam sterilization honorees experiences demonstrates awarded recognition techniques first aid kits johnsons caring others combined discovery development baby powder bandaid brand innovative research science makes prezista darunavir treatment adhesive bandagesinvented difference hiv infection patient says employee earle dickson johnson johnson enables us thank breathtaking next johnson johnson grew new cutting edge technology says dont get used portrait innovation since generations johnson johnson employees brought forth transformative ideas products every invention every product every breakthrough powered people inspired caring landmark inventions products guide photo inside back cover learn wwwjnjcomourhistory johnson johnson annual reportour caring caring women children arah omega mebendazole treatment intestinal mortality declined percent worms children see companys hospitals surveyed kenya yu haixia annual report extended support china variety safe birth programs mobile health mothers significant expansion mobile health alessandra joy mother megan johnson initiatives countries high infant megan johnsons life far megans united states share mortality rates high mobile second pregnancy seems much harder something common penetration bangladesh china first middletown india mexico nigeria south africa conn mom using textbaby mothers service help messages reminders lives touched safe pregnancy birth programs textbaby help put ease sarah omega suffered years relaxed better johnson johnson incontinence social rejection baby says network community fistula injury resulting textbaby offers free health based partners working prolonged childbirth first time information expectant mothers could afford genuine smile says babys first year life easily together better health recalling day repaired accessible cell phones save improve lives united nations population fund landmark project made possible unfpa estimates publicprivate partnership includes caring health mothers million women untreated fistulas government corporations academic children pillar approximately institutions professional associations philanthropic initiatives last develop condition year trial agencies nonprofit organizations years says sharon dagostino vice johnson johnson supports unfpa johnson johnson founding president worldwide corporate key hospitals addis ababa sponsor textbaby service contributions johnson johnson fistula hospital ethiopia expanded commitment johnson johnson continued comprehensive community based multimilliondollar multiyear longstanding legacy fiveyear rehabilitation dar es salaam pledge support significantly commitment response united tanzania prevent treat fistula accelerate reach textbaby nations call action achieve help survivors rebuild lives united states millennium development goals mdg another example safe birth reducing mortality women program yu haixias son maximizing impact children commitment aims song xiaoyan born could impact peoples lives help many million women breathe nurses performed vitally important aspect giving year next five years lifegiving resuscitation xiaoyan one caring company says dagostino reaching countries thousands children given new life equally important support philanthropic programs chinas neonatal resuscitation provide communitybased partners responsibility share program nrp joint effort provide strategic guidance well resources bring latest johnson johnson chinese ministry financial support working knowledge technology medicine health american academy organizations measure results improve lives women pediatrics address birth asphyxia ensure programs children says dagostino baby unable breathe birth desired effect mdg commitment includes since launch late last decade johnson johnson research development efforts bring medical professionals operating companies provided forward new treatments hiv provinces trained billion grants product tuberculosis see related story studies conducted chinese donations patient assistance million doses annually ministry health birth asphyxia touching lives around world johnson johnson annual reportsafe birth programs surgery repaired fistula sarah omega top went victim social stigma social advocate unfpa campaign end fistula yu haixia bottom left remembers vividly horrifying silence babys first cry sign could breathe nurses performed lifegiving resuscitation megan johnson bottom right using textbaby help second pregnancy tries take best care daughter alessandra baby ontheway read stories companys philanthropic efforts wwwjnjcomourcaring johnson johnson annual report recycling material document policies meaningful life iraci develop stronger social leandro dos santos finds reshaping lives infrastructure purpose mantra social operational recycle earth infrastructure enable benefits cooperatives grow responsibly documented sa based united policies reduce risks nations universal declaration recycling cooperative waste material recycling making catadores human rights convention futura jos dos living working attractive businesses rights child campos brazil strong cooperatives cooperatives says michael maggio various international labour community people create purposefilled way vice president global organization conventions otherwise invisible society life providing level strategic design operations includes nine basic principles members proudly work dignity members johnson johnson thats documented policies provides service poor formally important child labor discrimination larger community serves unemployed project provide valuable recycled health safety significant purpose phoenix started help content suppliers seeing great progress work important futura cooperatives companies like us especially futura people outside learn brazil responsibly foster increasingly interested using relationships one recycling us lifestyle improve materials suppliers suzano says iraci leandro dos santos livelihood catadores project phoenix modeled makes packaging proclaims futura operated largely sa global social bandaid brand adhesive mantra recycle unwritten social code accountability standard bandages says maggio earth benefits cooperation project phoenix ethical working conditions ultimately wed like see iraci catador one helps cooperatives improve developed social catadores achieve sa many collect process operational processes accountability international certification johnson johnson annual reportfirst row committees board board william c weldon chairman board directors audit directors chief executive officer audit committee chairman executive composed entirely indepen committee dent directors helps board second row left right oversee companys finan mary sue coleman phd cial accounting reporting president university michigan practices recommends independent public auditor james g cullen appointment board retired president chief reviews performance operating officer bell atlantic addition committee corporation monitors adequacy third row left right internal accounting practices ian e l davis procedures controls managing director emeritus reviews companys financial former worldwide managing reporting process disclo director mckinsey company sure procedures helps michael e johns md board oversee companys chancellor emory university legal compliance programs fourth row left right susan l lindquist phd james g cullen chairman member former director mary sue coleman phd whitehead institute ian e l davis biomedical research professor leo f mullin biology massachusetts institute technology compensation benefits compensation benefits anne mulcahy former chairman committee composed entirely chief executive officer independent directors xerox corporation establishes companys executive compensation fifth row left right philosophy principles leo f mullin approves annual compen retired chairman sation longterm chief executive officer incentives companys delta air lines inc directors executive offi william perez cers committee also senior advisor greenhill co reviews philosophy inc retired president policies nonboard chief executive officer management compensation wm wrigley jr company committee determines sixth row left right management compensation charles prince establishes perquisites chairman sconset group llc compensation policies senior counselor albright nonexecutive employees capital management llc additionally committee retired chairman chief oversees management executive officer citigroup inc various retirement david satcher md phd pension longterm incentive director center excellence savings health welfare health disparities plans cover director satcher health companys employees leadership institute charles prince chairman poussaintsatchercosby chair michael e johns md mental health morehouse anne mulcahy school medicine former william perez us surgeon general johnson johnson annual report finance directors one corporate officers executive committee finance committee companys vice chairmen william c weldon executive committee exercises authority executive committee chairman board directors johnson johnson board intervals vice presidents corporate chief executive officer principal management board meetings affairs government affairs chairman executive committee group responsible finance committee policy johnson johnson operations allocation composed chairman supply chain dominic j caruso resources company vice president board presiding committee oversees finance chief financial officer director leo f mullin chairman coordinates activities executive committee ian e l davis consumer pharmaceuticals william c weldon chairman alex gorsky douglas k chia medical devices james g cullen clifford e holland corporate secretary diagnostics business segments susan l lindquist phd assistant general counsel subsidiary within brian perkins business segments stephen j cosgrove nominating corporate david satcher md phd exceptions managed corporate controller governance ajit shetty phd citizens country nominating corporate laverne h council located governance committee vice president composed entirely science technology chief information officer independent directors science technology worldwide chairmen responsible overseeing advisory committee composed russell c deyo vice president consumer group corporate governance matters independent directors general counsel jesse j wu reviewing possible candidates companys vice president executive committee board membership science technology helps medical devices recommending nominees board scientific matters peter fasolo diagnostics group election committee impacting companys worldwide vice president michael f mahoney also responsible overseeing business including monitoring human resources pharmaceuticals group process performance strategy effectiveness executive committee joaquin duato evaluations board companys research paul stoffels committees additionally development organization alex gorsky vice chairman committee reviews reviewing effectiveness executive committee companys executive scientific aspects company group succession plans companys product safety raymond c jordan chairmen executive resources processes overseeing major vice president roberto de marques business development activities public affairs william perez chairman related acquisition corporate communication michael j f del prado james g cullen new science technology anne mulcahy identifying understanding sherilyn mccoy seth h z fischer vice chairman charles prince significant new science gary fischetti executive committee technology policy issues jane griffiths trends john papa public policy treasurer guy j lebeau md public policy advisory david satcher md phd karen licitra committee reviews chairman brian perkins vice president patrick mutchler companys policies programs mary sue coleman phd corporate affairs practices public health michael e johns md david norton issues regarding environ susan l lindquist phd michel paul ment health safety garry neil md employees committee jacques peeters also reviews companys gary j pruden governmental affairs policies public policy marc e robinson issues facing company michael e sneed committee advises pericles p stamatiades makes recommendations board issues kim taylor appropriate public nicholas j valeriani policy advisory committee composed independent johnson johnson annual reportcorporate governance managements responsibility johnson johnson guided values set forth credo pricewaterhousecoopers llp independent registered public created general robert wood johnson theseprinciples accountingfirm engaged perform integrated audit guided us years continue set toneof consolidated financial statements internal control financial integrity theentire company levels employees reporting thereport independent registered public accounting johnson johnson committed ethical principles embod firm ied credo principles woven theaudit committee board directors composed fabric company solely independent directors financial knowledge thevalues articulated credo extend accounting experience provide appropriate oversight review internal financial responsibilities johnson johnson shareholders control matters key accounting financial reporting issues investors management johnson johnson audit committee regular basis addition inde responsible theintegrity objectivity accompanying pendent auditors general counsel chief financial officer financial statements related information also responsi chief compliance officer vice president internal ble ensuringthat financial data reported accurately audit regularly meet private sessions audit committee manner facilitates understanding data discuss results work including observations evidence commitmentto responsibility adequacy internal financial controls thequality financial maintain welldesigned system internal accountingcontrols reporting confirmation properly discharging encourage strong effective corporate governance responsibilities relevant matters board directors continuously review business results executive committee continuously involved strategic choices focus financial stewardship review financial results well developing understanding corporate staff professionally trained internal auditors strategies key initiatives longterm growth intentis travel worldwide monitor system internal accounting ensure maintain objectivity business assessments controls designedto provide reasonable assurance assets constructively challenge approachto business opportunities safeguarded thattransactions events recorded properly issues monitor business results related controls internal controls includeselfassessments internal reviews consolidated financial statements financial datathat operating companies follow prepared conformity accountingprinciples company continuedto invest significant time generally accepted united states america include resources order ensure compliance section amounts based upon best judgments commit sarbanesoxley act based work performed ted present discuss results operations clear concludedthat internal control financial reporting transparent manner order provide timely comprehensive waseffective january refer managements understandable information shareholders report internal control financial reporting require management teams operating compa nies certify compliance policy business conduct sets forth companys commitmentto conduct busi ness affairs integrity comply governing laws regulations systematic program designed ensure compliance policies andprovide means reporting concerns violations policy please visit website william c weldon dominic j caruso wwwinvestorjnjcomgovernanceconductcfm view policy chairman board directors vice president finance business conduct chief executive officer chief financial officer table contents managements discussion analysis audited consolidated financial statements organization business segments consolidated balance sheets results operations consolidated statements earnings analysis sales business segments consolidated statements equity analysis consolidated earnings provision consolidated statements cashflows taxes income notes consolidated financial statements liquidity capital resources report independent registered public accountingfirm information managements report internal control cautionary factors may affect future results financial reporting supporting schedules summary operations statistical data shareholder return performance graphs reconciliation nongaap financial measures johnson johnson annual report managements discussion andanalysis results operations financial condition organization business segments managements objectives thecompany manages within strategic framework aimed description company business segments achieving sustainable growth accomplishthis companys johnson johnson subsidiaries company management operates business consistent certain strate approximately employees worldwide engaged gic principles proven successful time end research development manufacture sale broad range company participates growth areas human health care products thehealth care field thecompany conducts business committed attaining leadership positions growth areas virtually countries worldwith primary focus development high quality innovative products products related human health wellbeing services new products introduced within past five years thecompany organized three business segments accounted approximately sales bil consumer pharmaceutical medical devices diagnostics lion sales invested research development theconsumer segment includes broad range products usedin investment reflects managements commitmentto impor baby care skin care oral care woundcare womens health tance ongoingdevelopment new differentiated products care fields well nutritional overthecounter pharmaceuti services sustain longterm growth cal products andwellness prevention platforms theseproducts operating companies located marketed general public sold retail outlets countries thecompany views principle decentralized man anddistributors throughout world thepharmaceutical segment agement asset fundamental success broadly includes products following areas antiinfective antipsy based business also fosters entrepreneurial spirit combining chotic contraceptive dermatology gastrointestinal hematology extensive resources large organization ability immunology neurology oncology pain management virology anticipate react quickly local market changes challenges theseproducts distributed directly retailers wholesalers company committed developing global business lead health care professionals prescription use themedical devices ers drive growth objectives businesses managed diagnostics segment includes broad range products distrib longterm order sustain leadership positions achieve growth uted wholesalers hospitals retailers used principally provides enduring source valueto shareholders professional fields physicians nurses therapists hospitals diag credo unifies management team companys nostic laboratories clinics theseproducts includebiosense dedicated employees achieving objectives provides websters electrophysiology products cordis circulatory disease common set values serve constant reminder management products depuys orthopaedic joint reconstruction companys responsibilities customers employees communi spinal care neurological sports medicine products ethicons ties shareholders thecompany believes basic surgical care aesthetics womens health products ethicon principles along overall mission improving quality endosurgerys minimally invasive surgical products andadvanced oflife peopleeverywhere enable johnson johnson sterilization products lifescans blood glucose monitoring continue beamong leaders health care industry insulin delivery products orthoclinical diagnostics professional diagnostic products andvistakons disposable contact lenses results operations thecompanys structure based upon principle decentralized management theexecutive committee analysis consolidated sales johnsonjohnson principalmanagement group responsible worldwide sales decreased billion compared forthe operations allocation resources company decrease increase committee oversees coordinates activities thesesales changes consisted following consumer pharmaceutical medical devices diagnostics business segments sales decreaseincrease due volume product lines company competes compa nies local andglobal located throughout world competi price tion exists product lines without regard number size currency competing companies involved competition research total involvingthe development improvement new existing products andprocesses particularly significant thedevelopment sales us companies billion billion new innovative products important companys billion represents decrease success areas business also includes protecting decrease decrease thecompanys portfolio intellectual property thecompetitive sales international companies billion environment requires substantial investments continuing billion billion represents research maintaining sales forces addition thedevelop increase decrease ment maintenance customer demand thecompanys increase consumer products involves significant expenditures advertising promotion johnson johnson annual reportincluded increase minimum medicaid rebate rate us also extended rebate drugs provided international sales medicaid managed care organizations impact years inbillions dollars wasan increase sales rebates reducingsales revenue approxi mately million full year impact sales us legislation estimated million international beginning companies sell branded prescription drugs specified us government programswill pay annual non tax deductiblefee based allocation companys market share totalbranded prescriptiondrug salesfrom prioryear estimate impact company mil lionbeginning company required pay ataxdeductible excise tax imposed sale certain fiveyear compound annual growth rates worldwide medical devices us international sales respectively tenyear compound annual growth rates worldwide us salesby andinternational sales respectively segment inbillions dollars sales geographic consumer region pharmaceutical inbillions dollars medicaldevices anddiagnostics us europe westernhemisphere excludingus asia pacific africa analysis sales business segments consumer segment sales europe experienced decline including opera consumer segment sales billion decrease tional growth negative impact currency change due operational sales thewestern hemisphere excluding us achieved decline partially offset positive currency impact us con growth including operational decline sumer segment sales billion decrease interna increase related thepositive impact currency sales tional sales billion increase operational asiapacific africa region achieved growth including decline offset positive currency impact operational growth increase related theoverthecounter otc pharmaceuticals nutritionals positive impact currency franchise sales billion decrease company acus sales negatively impacted voluntary recalls certain tomer represented total consolidated revenues otc products announced earlier year suspension results benefited inclusion rd week production mcneil consumer healthcares fort washington seenote consolidated financial statements annual pennsylvania facility mcneils recalls products manufactured closing date details thecompany estimated fiscal year las piedras fort washington facilities impacted total growth rate enhanced approximately due year sales approximately million rd week alternate supplies products planned available latter half mcneil consumer healthcare submitted us health care reform comprehensive action plan cap us food drug patient protection affordable care act health administration fda july encompasses among careand educationreconciliation act signed law items training resources capital investments quality march newly enacted health care reform legislation manufacturing systems across mcneil organization major consumer franchise sales change dollars millions vs vs otc pharmaceuticals nutritionals skin care baby care womens health oral care wound careother total managements discussion analysis results operations financial condition company continues communicate fda remediation procritepoetin alfa eprexepoetin alfa com actions schedule commitments madein thecap bined sales billion decline compared skin care franchise sales billion decline prior year lower sales procritand eprexwere primarily compared prior year due part temporary reduc due declining markets erythropoiesis stimulating agents tion shipments neutrogena products due product supply esas eprexalso experienced increased competition constraints partially offset growth aveeno johnsons risperdalconstarisperidone longacting injectable adult le petit marseillaisand dabaoskin care lines antipsychotic achieved salesof billion representing baby care franchise sales grew billion increase compared prioryear solid growth primarily due growth asia pacific region partially offset achieved outside us strong growth japanin impact economic situation venezuela thewomens us successful launch invegasustennapaliperi health franchise sales billion decrease primarily done palmitatealso increased growth longacting due increased competitive pressures impact eco injectable antipsychotic market nomic situation venezuela theoral care franchise sales levaquinlevofloxacinfloxinofloxacin sales billion decrease primarily due divestiture billion decline versus prior year primarily due efferdenteffergripbrands fiscal fourth quarter decline market increased penetration generics lower sales mouth rinses toothbrushes united market exclusivity us expires june theexpiration states thewound careother franchise sales billion ofa products market exclusivity likely result significant decrease primarily due private label competition reduction sales slower category growth concertamethylphenidate hcl product thetreat consumer segment sales billion ment attention deficit hyperactivity disorder adhd achieved decrease change due opera sales billion decrease compared tional growth negative currency impact us consumer prior year sales growth us impacted lower market segment sales billion decrease international share health care reform legislation enacted march sales billion decrease growth resulting changes rebates medicaid managed care organ achieved operations decrease resulting izations november company entered us negative impact currency fluctuations supply distribution agreement watson laboratories inc distribute authorized generic version concertabeginning pharmaceutical segment may authorized generic launch likely result pharmaceutical segment sales billion significant reduction concertasales decrease operational decline velcadebortezomib product thetreatment mul positive currency impact us sales billion tiple myeloma thecompany commercial rights decrease international sales billion europe rest worldoutside us achieved sales increase included operational growth billion representing increase compared positive currency impact pharmaceutical segment sales prior year reduced approximately million result aciphexparietrabeprazole sodium sales us health care reform legislation billion decline versus prior year due increased remicadeinfliximaba biologic approved treatment competition generics category number immune mediated inflammatory diseases achieved topamaxtopiramate experienced sales decline salesof billion growth prior year ofcompared prior year market exclusivity us export sales grew versus prior year primarily driven topamaxexpired march us inseptember market growth remicadeis competing market european countries multiple generics entered experiencing increased competition due new entrantsincluding market loss market exclusivity topamaxpatent successful launches stelaraustekinumab resulted significant reduction salesin us simponigolimumab expansion indications andeurope existing competitors pharmaceutical sales billion represent ing growth prior year contributors increase sales stelaraustekinumab simponigolimumab major pharmaceutical product revenues change dollars millions vs vs remicadeinfliximab procriteprexepoetin alfa risperdalconstarisperidone levaquinfloxinlevofloxacinofloxacin concertamethylphenidate hcl velcadebortezomib aciphexparietrabeprazole sodium topamaxtopiramate pharmaceuticals total prior year amounts reclassified conformto current presentation johnson johnson annual reportprezistadarunavir intelenceetravirine nucynta bythe divestiture breast care business third quarter tapentadol invega sustennapaliperidone palmitate growth partially offset lower sales duragesic theethicon franchise achieved sales billion fentanyl transdermal fentanyl transdermal systemand increase prior year thegrowth attributable risperdalrisperidone oral due continued genericcompetition sales newly acquired products fromacclarent inc addition several new compounds filed regulatory growth sutures mentor biosurgical womens health approval included abiraterone acetate investigational urology mesh product lines agent thetreatment metastatic advanced prostate cancer thevision care franchise achieved sales billion granted priority review us accepted accel increase prior year primarily driven day erated assessment europe telaprevir developed collabora acuvuetrueye acuvueoasysfor astigmatism tion vertex pharmaceuticals incorporatedfor hepatitis c day acuvuemoist partially offset lower sales filed accepted accelerated assessment europe reusable lenses company novartis ag ciba tmc rilpivirine hiv treatmentnave patients vision corporation ciba vision ag agreed resolve filedin theus europe rivaroxaban anticoagulant pending patent litigation worldwide basis enabling codeveloped bayer healthcare filed us company reenter markets france netherlands prevention stroke patients atrial fibrulation company sales cordis franchise billion decline also responded fda complete response letter review versus prior year thedecline reflects lower sales therivaroxaban filing preventing deep vein thrombosis pul cyphersirolimuselutingcoronary stent due increased global monary embolism followingtotal knee hip replacement surgery competition thedecline partially offset stronggrowth pharmaceutical segment sales billion ofthebiosense webster business decrease operational decline sales thediabetes care franchise billion remaining due negative impact currency fluc increase prior year primarily attributable tuations us sales billion decrease interna growth us asia pacific region partially offset sales tional sales billion decrease included decline europe operational growth decrease resulting theorthoclinical diagnostics franchise achieved sales negative impact currency fluctuations billion increase prior year growth primarily attributable sales vitros medicaldevicesand diagnostics segment analyzers partially offset lower sales donor screening primarily themedical devices diagnostics segmentachieved sales due selective screening chagas testing us billion representing increase themedical devices diagnostics segmentachieved sales prior year operational growth positive currency billion representing increase impact us sales billion increase prior year operational growth negative currency prior year international sales billion increase impact us sales billion increase prior year growth operations prior year international sales billion decrease positive currency impact growth operations decrease thedepuy franchise achieved sales billion resulting negative impact currency fluctuations increase prior year growth primarily due toan increase knee mitek sports medicine product lines analysis consolidated earnings outside us growth hip product line pressure provision taxes income pricing continuedas result economic trends however new product launches incremental sales newly acquired products consolidated earnings provision taxes income micrus endovascular corporation mitigated increased billion billion compared theimpact august depuy orthopaedics inc depuy billion earned increase theincrease announced worldwide voluntary recall asrxlacetabular primarily related lower selling marketing administrative system depuyasrhip resurfacing system used hip expenses due costcontainment actions resulting replacement surgery principally sold restructuring plan initiated implemented incomefrom ethicon endosurgeryfranchise achieved sales bil litigation settlements gain divestiture breast lion increase overthe prior year wasattributable care business ethicon endosurgery inc partially offset growth endoscopy advanced sterilization harmonic costs associated product liability expense impact surgrx ensealproduct lines growth waspartiallyoffset otc depuyasrhip recalls additional offsets lower major medical devices diagnostics franchise sales change dollars millions vs vs depuy ethicon endosurgery ethicon vision care cordis diabetes care orthoclinical diagnostics total managements discussion analysis results operations financial condition net selling prices pharmaceutical business due us health unfavorable product mixattributable loss market exclusiv care reform price reductions certain medical devices ity topamaxcontributed increase diagnostics businesses decrease compared decrease inthe percent sales selling marketing adminis billion primarily related lower sales trative expenses compared prior year primarily due negative impact product mix lower interest incomedue lower costcontainment initiatives principally resulting restruc rates interest earned restructuring charges billion turing plan implemented thedecrease partially offset partially offset lower selling marketing administra lower netselling prices pharmaceutical business due tive expenses due costcontainment efforts across busi us health care reform price reductions certain medical nesses earnings included purchased inprocess research devices diagnostics businesses development iprd charges billion increased cost products sold percent sales increased investment spending selling marketing administrative compared prior year primarily due continued negative expenses utilized proceeds associated divestiture impact product mix inventory writeoffs associated professional wound care business ethicon inc per therestructuring activity additionally included non cent sales consolidated earnings provision taxes recurring positive items decrease percent incomein versus sales selling marketing administrative expenses thesections follow highlight significant components compared prior year primarily due costcontainment efforts changes consolidated earnings provision taxes across businesses annualized savings recognized income restructuring program addition company utilized proceeds associated divestiture cost products sold selling marketing andadministrative professional wound care business ethicon inc fund expensescost products sold andselling marketing adminis increased investment spending trative expenses percent sales follows cost products sold percent sales remained sales flat prior year thechange mix businesses cost products sold higher sales growth consumer business slight sales percent point increase prior year decline pharmaceutical business negative impact cost products sold percent sales selling marketing administrative expenses set manufacturing efficiencies nonrecurring positive items percent point decreaseincrease negative items increase prior year percent sales selling marketing administrative expenses cost products sold percent sales increased com primarily due change mix businesses whereby pared prior year primarily due costs associated greater proportion sales attributable consumer seg impact otc recall remediation efforts consumer ment higher selling marketing administrative spend business lower netselling prices pharmaceutical business ing additionally company utilized gain associated due us health care reform price reductions certain divestiture professional wound care business medical devices diagnostics businesses additionally ethicon inc fund increased investment spending par tially offset ongoingcostcontainment efforts research development expense excluding purchased inprocess research development charges segment business asfollows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices diagnostics total research development expense percent decreaseincrease prior year percent segment sales research development expenseresearch development evolving global environment fiscal fourth quarter activities represent significant part companys business thecompany recorded pretax charge billion ofwhich theseexpenditures relate development new products million included cost products sold improvement existing products technical support products see note consolidated financial statements compliance governmental regulations theprotection additional details related restructuring ofconsumers patients thecompany remains committed purchased inprocess research developmentbeginning investing research development aim delivering accordance us gaap business combinations pur high quality innovative products chased inprocess research development iprd longer restructuringin company announced global restructur expensed capitalized tested impairment company ing initiatives expected generate pretax annual cost capitalized approximately billion iprd primarily savings approximately billion fully implemented associated acquisitions acclarent inc respivert ltd theassociated savings provided additional resources micrus endovascular corporation company capitalized bil invest new growth platforms ensure successful launch lion iprd primarily associated acquisitions companys many new products andcontinued growth core cougar biotechnology inc substantially assets businesses provide flexibility adjust changed rights elan related alzheimers immunotherapy program johnson johnson annual reportin company recorded charge iprd mil consumer segmentin consumer segment operating profit lion tax related acquisitions amicab decreased theprimary reasons thedecrease surgrx inc healthmedia inc omrix biopharmaceuticals inc inthe operating profit lower sales higher costs associated healthmedia inc privately held company creates webbased recall certain otc products andthe suspension behavior change interventions accounted million tax production atmcneil consumer healthcares fort washington ofthe iprd charges included operating profit pennsylvania facility consumer segment operating profit theconsumer segment iprd charges following decreased theprimary reasons thedecrease acquisitions included operating profit medical operating profit million restructuring charges partially devices diagnostics segment amic ab swedish developer offset costcontainment initiatives ofin vitro diagnostic technologies use pointofcare pharmaceutical segmentin pharmaceutical segment operat nearpatient settings outside physical facilities clinical ing profit increased theprimary reasons laboratory accounted million tax iprd increase operating profit lower manufacturing costs charges surgrx inc privately held developer advanced gain divestiture benefits fromcost improvement initiatives bipolar tissue sealing system used ensealfamily devices related restructuring plan implemented partially accounted million tax iprd charges omrix bio set million expense related litigation matters pharmaceuticals inc fully integrated biopharmaceutical company increased product liability expense impact newly develops markets biosurgical immunotherapy prod enacted us health care reform legislation pharmaceutical ucts accounted million tax iprd charges segment operating profit decreased theprimary income expense netother income expense net reasons thedecrease operating profit million includes royalty income gains losses related sale restructuring charges million litigation expense negative writedown certain investments equity securities held product mix dueto loss market exclusivity topamax johnson johnson development corporation gains losses risperdaloral disposal property plant equipment currency gains medical devices diagnostics segmentin medical losses noncontrolling interests litigation settlements devices diagnostics segment operating profit increased favorable change billion income expense net improved operating profit due gain compared primarily due net gain billion net litigation matters gain divestiture litigation settlements gain divestiture businesses breast care business recorded partially offset partially offset product liability expense increased product liability expense million costs associ income expense net included net litigation ated depuy asrhip recall program price reductions settlements billion income expense net incertain medical devices diagnostics businesses included incomefrom net litigation settlements awards operating profit medical devices diagnostics segment billion gain billion divestiture increased improved operating profit due professional wound care business ethicon inc toa million gain net litigation settlements favorable prod uct mix manufacturing efficiencies cost containment initiatives operating profit segment related selling marketing administrative expenses operating profits segment business follows partially offset million restructuring charges percent interest income expenseinterest incomein increased segment sales million prior year due higher average cash balances dollars millions cash cash equivalents marketable securities totaled bil consumer lion end averaged billion compared pharmaceutical billion average cash balance theincrease medical devices average cash balance primarily due cash generated diagnostics operating activities net cash proceeds litigation matters total divestitures less expenses allocated interest expense relatively flat compared segments due lower average rate despite higher debt balance earnings provision total debt balance end billion compared taxes income billion atthe end thehigher average debt balance see note consolidated financial statements details billion versus billion due amounts allocated segments include interest income expense noncontrolling increased borrowings thecompany increased borrowings capital interests general corporate income expense izing favorable terms capital markets theproceeds notes used general corporate purposes operating profit interest incomein decreased million ascom bysegment pared due lower rates interest earned despite higher inbillions dollars average cash balances thecash balance including marketable securities billion end averaged consumer billion compared billion average cash balance pharmaceutical theincrease average cash balance primarily medicaldevices anddiagnostics dueto cash generated operating activities interest expense increased million compared due higher debtbalance thenetdebt balance atthe end billion compared billion end thehigher average debt balance billion managements discussion analysis results operations financial condition versus billion primarily related fundingacquisi tions investments purchase companys common stock ongoing common stock repurchase program announced july interest incomein decreased million compared due lower rates interest earned despite higher average cash balances thecash balance including marketable securities billion end averaged billion ascompared billion average cash balance increase average cash balance primarily due cash generated operating activities interest expense increased million com pared due higher debtbalance second half company converted shortterm debt fixed financing market risk longterm debt higher interest rates thenetdebt balance atthe thecompany uses financial instruments manage impact end billion compared billion end offoreign exchange rate changes cash flows accordingly thehigher debt balance primarily due company enters forward foreign exchange contracts protect thepurchase companys common stock ongoing value certain foreign currency assets liabilities common stock repurchase program announced july hedge future foreign currency transactions primarily related prod andto fundacquisitions uct costs gains losses contracts offset gains losses underlying transactions appreciation provision taxes incometheworldwide effective incometax us dollar january market rates wouldincrease rate unrealized value companys forward contracts mil tax rate decreased compared due decreases lion conversely depreciation us dollar taxable incomein higher tax jurisdictions relative taxable income january market rates woulddecrease unrealized value lower tax jurisdictions certain us tax adjustments companys forward contracts million either scenario tax rate decreased compared due increases gain loss forward contract wouldbe offset gain taxable incomein lower tax jurisdictions relative taxable income loss underlying transaction therefore wouldhave higher tax jurisdictions noimpact future anticipated earnings cash flows thecompany hedges exposure fluctuations currency liquidity capital resources exchange rates effect certain assets liabilities foreign currency entering currency swap contracts liquidity cash flows cash cash equivalents billion end change spread us foreign interest rates compared billion end theprimary sources companys interest rate sensitive financial instruments would either cash contributed billion increase versus prior increase decrease unrealized value companys swap year billion cash generated operating activities contracts approximately million either scenario matu billion net proceeds longandshortterm debt rity gain loss swap contract wouldbe offset gain billion proceeds disposal assets themajor uses loss underlying transaction therefore wouldhave cash capital spending billion acquisitions bil impact future anticipated cash flows lion net investment purchases billion dividends share thecompany enter financial instruments holders billion repurchase common stock net trading speculative purposes company policy proceeds exercise options billion entering contracts parties atleast cash flows operations billion equivalent credit rating thecounterparties contracts major sources cash flow net incomeof billion major financial institutions significantconcentra adjusted noncash charges depreciation amortization stock tion exposure one counterparty management believes based compensation deferred tax provision billion risk loss remote theremaining changes operating cash flow increases thecompany access substantial sources funds accounts receivable inventories assets numerous banks worldwide september company company continuedto access liquidity secured new day credit facility total credit available commercial paper market additional details company approximates billion expires september borrowings see note consolidated financial statements interest charged borrowings credit line agree thecompany anticipates operating cash flows existing ment based either bids provided banks prime rate credit facilities access commercial paper markets london interbank offered rates libor plus applicable margins provide sufficient resources fund operating needs commitmentfees agreement material total borrowings end bil lion billion respectively theincrease borrowings result financing general corpo rate purposes continuation companys common stock repurchase program announced net cash cash current marketable securities net debt bil lion compared net cash billion total debt repre sented total capital shareholders equity total debt total capital shareholders equity johnson johnson annual reportpershare end compared disclosures actual results may may differ esti yearend increase mates thecompany believes understanding certain key summary borrowings found note accountingpolicies estimates essential achieving consolidated financial statements insight companys operating results financial condition thesekey accountingpolicies include revenue recognition income contractualobligations andcommitments taxes legal selfinsurance contingencies valuation longlived thecompanys contractual obligations primarily leases debt assets assumptions used determine amounts recorded unfunded retirement plans significant obliga pensions employee benefitplans accountingfor tions satisfy theseobligations company use cash stockoptions operations thefollowing table summarizes companys contrac revenue recognitionthecompany recognizes revenue fromprod tual obligations aggregate maturities january uct sales whengoods shipped delivered title risk see notes consolidated financial statements ofloss pass customer provisions certain rebates sales forfurther details incentives trade promotions coupons product returns dis longterm interest unfunded counts customers accounted reductions sales debt debt retirement operating period related sales recorded dollars millions obligations obligations plans leases total product discounts granted based terms arrange ments direct indirect market participants well asmarket conditions includingprices charged competitors rebates largest medicaid rebate provision esti mated based contractual terms historical experience trend analysis projected market conditions various markets served thecompany evaluates market conditions products total groups products primarilythrough analysis wholesaler thirdparty sellthrough market research data well internally generated information tax matters see note consolidated financial statements sales returns generally estimated recorded based historical sales returns information products exhibit sharerepurchase dividends unusual sales return patterns due dating competition july company announced board directors marketing matters specifically investigated analyzed part approved stock repurchase program authorizing company accountingfor sales return accruals buy back billion companys common stock sales returns allowances represent reserve products january current stock repurchase program may returned due expiration destruction thefieldorin spe completed thecompany repurchased aggregate million cificareas product recall returns reserve based historical shares johnson johnson common stock cost bil return trends product market percent gross sales lion thecompany funded share repurchase program accordance companys accountingpolicies company combination available cash debt addition company generally issues credit customers returned goods annual program repurchase shares use employee companys sales return reserves accounted accordance stock incentive plans us gaap guidance revenue recognition right thecompany increased dividend th con return exists sales return reserves recorded full sales value secutive year cash dividends paid per share sales returns consumer andpharmaceutical segments compared dividends per share almost exclusively resalable sales returns certain franchises per share thedividends distributed follows themedical devices diagnostics segmentare typically resal able material thecompany rarely exchanges products first quarter inventory returned products thesales returns reserve second quarter total company ranged annual net third quarter trade sales prior three fiscal reporting years promotional programssuch product listing allowances fourth quarter cooperative advertising arrangements recorded year total incurred continuingpromotional programs include coupons volumebased sales incentive programs theredemption cost january board directors declared regular quar consumer coupons based historical redemption experience terly cash dividend per share payable march product value volumebased incentive programs based shareholders record march thecompany expects estimated sales volumes theincentive period recorded continuethepractice paying regular cash dividends products sold thecompany also earns service revenue copromotion certain products years presented service information revenues less total revenues included sales customers thesearrangements evaluated determine critical accounting policies estimates managements discussion analysis results operations appropriate amounts bedeferred andfinancial condition based companys consolidated addition company enters collaboration arrange financial statements prepared accordance ments contain multiple revenue generating activities accountingprinciples generally accepted us gaap revenue thesearrangements recognized activity preparation financial statements requires manage performed delivered based relative fair value upfront mentmake estimates assumptions affect amounts feesreceived part arrangements deferred recog reported revenues expenses assets liabilities related nized revenue earned obligation period see note managements discussion analysis results operations financial condition theconsolidated financial statements additional disclosures medicaldevicesand diagnostics segment oncollaborations balance balance reasonably likely changes assumptions used calculate beginning payments end theaccruals rebates returns promotions anticipated dollars millions period accruals period material effect financial statements thecompany currently discloses impactof changes assumptions accrued rebates quarterly annual filing material financial accrued returns statement impact accrued promotions tables thatshow progression accrued rebates subtotal returns promotions reserve doubtful accounts reserve reserve doubtful accounts cash discounts segment business fiscal years ended reserve cash discounts january january total consumer segment balance balance accrued rebates beginning payments end accrued returns dollars millions period accruals period accrued promotions subtotal accrued rebates reserve doubtful accounts accrued returns reserve cash discounts accrued promotions total subtotal reserve doubtful accounts includes reserve customerrebates million january million january recorded contra asset reserve cash discounts total income taxesincometaxes recorded based amounts refundable payable thecurrent year include results difference us gaap accounting tax reporting accrued rebates recorded deferred tax assets liabilities thecompany esti accrued returns mates deferred tax assets liabilities based current tax regula accrued promotions tions rates changes tax laws rates may affect recorded subtotal deferred tax assets liabilities future management reserve doubtful accounts believes changes estimates wouldnot material reserve cash discounts effect companys results operations cash flows total financial position accordance us gaap company adopted includes reserve customerrebates million atjanuary million standard related accountingfor uncertainty incometaxes january recorded contra asset thecodification prescribes recognition threshold measure pharmaceutical segment ment attribute financial statement recognition measure ment tax position taken expected taken tax return balance balance thecodification also provides guidance derecognition classifi beginning payments end cation matters see note consolidated financial dollars millions period accruals period statements information regarding incometaxes january january cumulative accrued rebates amounts undistributed international earnings approximately accrued returns billion billion respectively thecompany intends accrued promotions tocontinue reinvest undistributed international earnings subtotal expand international operations therefore us tax expense reserve doubtful accounts recorded respectto undistributed portion reserve cash discounts intended repatriation total legal self insurance contingenciesthe company records accruals various contingencies including legal proceedings accrued rebates product liability cases arise normal course business accrued returns accruals based managements judgment proba bility losses applicable actuarially determined esti accrued promotions mates additionally thecompany records insurance receivable subtotal amounts thirdparty insurers recovery probable reserve doubtful accounts appropriate reserves receivables recorded esti reserve cash discounts mated amounts may collected thirdparty insurers total company follows provisions us gaap record ing litigation related contingencies liability recorded loss includes reserve customerrebates million january million january recorded contra asset probable reasonably estimated best estimate includes additional sales rebates medicaid managed care organizations result aloss within arange accrued however estimate range health care reformlegislation better minimum amount accrued johnson johnson annual reportlonglivedand intangible assetsthecompany assesses changes behavior spending patterns purchasers changesin economic conditions andmakes assumptions regarding health care products services including delaying medical estimated future cash flows evaluating value procedures rationing prescription medications reducing companys property plant equipment goodwill intangible frequency physician visits foregoinghealth care insurance assets assumptions estimates may change coverage result current global economic downturn timeitmay may necessary thecompany record maycontinue impact companys businesses impairment charges thecompany also operates environment becomeincreasingly hostile intellectual property rights generic employee benefit plansthecompany sponsors various retirement drug firms filed abbreviated new drug applications andas pension plans including defined benefit defined contribution seeking market generic forms mostof thecompanys key phar termination indemnity plans cover employees maceutical products prior expiration applicable patents worldwide plans based assumptions discount covering products event company successful rate expected return plan assets expected salaryincreases defending patent claims challenged anda filings health care cost trend rates see note consolidated finan generic firms introduce generic versions product cial statements details rates effect issue resulting potential forsubstantial market share rate change wouldhave companys results operations revenue losses product forfurther information seethe stock based compensationthecompany recognizes compensa discussion litigation filers abbreviated new drug tion expense associated issuance equity instruments applications note consolidated financial statements employees services thefair value award esti mated date grant using blackscholes option valuation legal proceedings model expensed financial statements vesting thecompany involved numerous product liability cases period theinput assumptions used determining fair value united states many concern alleged adverse reactions theexpected life expected volatility riskfree rate dividend drugs medical devices thedamages claimed substantial yield see note consolidated financial statements company confident adequacy warnings additional information instructions usethat accompany products itis feasible predictthe ultimate outcomeof litigation however newaccounting pronouncements company believes cases product liability sub refer note consolidated financial statements recently stantially covered existing amounts accrued companys adopted accountingpronouncements recently issued account balance sheet selfinsurance program ing pronouncements yet adopted january thecompany also involved number patent trademark lawsuits well investigations incidental busi economic marketfactors ness theultimate legal financial liability company thecompany aware products used environment respectto claims lawsuits proceedings referred adecade policymakers consumers busi reasonably estimated however companys opin nesses expressed concerns rising cost health care ion basedon examination matters experience response concerns company longstanding date discussions counsel theultimate outcomeof legal policy pricing products responsibly theperiod proceedings net liabilities already accrued companys united states weighted average compound annual growth balance sheet expected material companys rate companys net price increases health care products financial position although resolution reporting period prescription overthecounter drugs hospitaland professional ofone matters couldhave material impacton products us consumer price index cpi thecompanys results operations cash flows period inflation rates continue effect worldwide see note consolidated financial statements economies consequently way companies operate information regarding legal proceedings company accounted operations venezuela highly inflation ary prior threeyear cumulative inflation rate sur common stock market prices passed face increasing costs company strives thecompanys common stock listed new york stock maintain profit margins cost reduction programs exchange symbol jnj thecomposite market price ranges productivity improvements periodic price increases johnson johnson common stock thecompany exposed fluctuations currency exchange rates change value us dollar compared high low high low allforeign currencies company sales incomeor first quarter expense wouldhave increased decreased translation second quarter foreign sales approximately million incomeby million third quarter thecompany faces various worldwide health care changes fourth quarter may continue result pricing pressures include health yearend close care costcontainment andgovernment legislation relating sales promotions andreimbursement managements discussion analysis results operations financial condition cautionary factors may affect future results annual report contains forwardlooking statements forward risks uncertainties include limited general looking statements notrelate strictly historical current facts industry conditions andcompetition economic factors anticipate results based managements plans sub interest rate currency exchange rate fluctuations technological jectto uncertainty forwardlooking statements may identified advances new products andpatents attained competitors chal bythe use words plans expects anticipates lenges inherent new product development including obtaining estimates words similar meaning conjunction regulatory approvals challenges patents significantlitigation among things discussions future operations financial adverse company impact business combinations financial performance companys strategyfor growth product develop distress bankruptcies experienced significant customers ment regulatory approval market position andexpenditures andsuppliers changes governmental laws regulations forwardlooking statements based current expectations us foreign health care reforms trends toward healthcare cost future events thecompany guarantee forward containment increased scrutiny healthcare industry gov looking statement accurate although company believes ernment agencies changes behavior spending patterns reasonable expectations assumptions purchasers healthcare products services manufacturing investors realize underlying assumptions prove inac difficulties delays product efficacy orsafety concerns resulting curate unknown risks uncertainties materialize actual inproduct recalls regulatory action results couldvary materially companys expectations thecompanys report theyear ended projections investors therefore cautioned place undue january includes exhibit discussion additional reliance forwardlooking statements thecompany factors couldcause actual results differ expectations undertake update forwardlooking statements result thecompany notes factors permitted private new information future events developments securities litigation reform act johnson johnson annual reportconsolidated balance sheets johnson johnson subsidiaries atjanuary january dollars millions except share pershare data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes incomenote prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwillnotes deferred taxes incomenote assets total assets liabilities shareholders equity current liabilities loans andnotes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income total current liabilities longterm debt note deferred taxes incomenote employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive incomenote retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements consolidated financial statements consolidated statements earnings johnson johnson subsidiaries dollars millions except pershare figures note sales customers cost products sold gross profit selling marketing administrative expenses research development expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes incomenote net earnings basic net earningspershare notes diluted net earnings per share notes cash dividends per share basic average shares outstanding notes dilutedaverage shares outstanding notes see notes consolidated financial statements johnson johnson annual reportconsolidated statements equity johnson johnson subsidiaries accumulated treasury comprehensive retained comprehensive common stock stock dollars millions note total income earnings income issued amount amount balance december net earnings cash dividendspaid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income balance december net earnings cash dividendspaid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges total comprehensive income balance january net earnings cash dividendspaid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans losses derivatives hedges total comprehensive income balance january see notes consolidated financial statements consolidated financial statements consolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcilenet earnings cash flows operating activities depreciation andamortization property intangibles stock basedcompensation purchased inprocess research development deferred tax provision accounts receivable allowances changes assets liabilities net effects fromacquisitions increasedecrease accounts receivable increasedecrease inventories increasedecrease accounts payable accrued liabilities increasedecrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financingactivities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents increase cash cash equivalents cash cash equivalents beginning year note cash cash equivalents endof year note supplemental cash flow data cash paid year interest incometaxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions see notes consolidated financial statements johnson johnson annual reportnotes consolidated financial statements summary significant accounting policies fiscal first quarter company adopted principles consolidation fasb standard related variable interest entities theadoption theconsolidated financial statements include accounts standard nothave impact companys results ofjohnson johnson subsidiaries thecompany inter operations cash flows financial position company accounts transactions eliminated fiscal first quarter company adopted new accountingguidance fair value measurements description company business segments disclosures guidance requires company disclosethe thecompany approximately employees worldwide amount significant transfers level level inputs engaged research development manufacture sale reasons thesetransfers well reasons broad range products thehealth care field thecompany transfers level fair value hierarchy addition conducts business virtually countries worldand pri guidance clarifies certain existing disclosure requirements mary focus products related human health wellbeing theadoption standard nothave material impact thecompany organized three business segments companys results operations cash flows financial position consumer pharmaceutical medical devices diagnostics theconsumer segment manufactures markets broad range recently issued accounting standards products usedin baby care skin care oral care woundcare adopted asof january womens health care fields well nutritional overthe fiscal second quarter fasb issued counter pharmaceutical products andwellness prevention plat accounting standard update related revenue recognition forms theseproducts marketed general public sold milestone method theobjective accounting standard retail outlets distributors throughout world update provide guidance defining milestone determin pharmaceutical segment includes products following areas ing may appropriate applythe milestone method antiinfective antipsychotic contraceptive dermatology gastroin revenue recognition research development transactions testinal hematology immunology neurology oncology pain man thisguidance effective prospective basis milestones agement virology theseproducts distributed directly achieved fiscal years interim periods within years retailers wholesalers health care professionals prescription beginning june theadoption standard use themedical devices diagnostics segmentincludes expected material impact companys results broad range products distributed wholesalers hospitals operations cash flows financial position retailers used principally professional fields physicians nurses therapists hospitals diagnostic laboratories clinics cash equivalents theseproducts include biosense websters electrophysiology prod thecompany considers securities maturities three months ucts cordis circulatory disease management products depuys less purchased becashequivalents orthopaedic joint reconstruction spinal care neurological sports medicine products ethicons surgical care aesthetics investments womens health products ethicon endosurgerys minimally shortterm marketable securities carried cost approxi invasive surgical products andadvanced sterilization products mates fair value investments classified availableforsale lifescans blood glucose monitoring andinsulin delivery products carried estimated fair value unrealized gains losses orthoclinical diagnostics professional diagnostic products recorded component accumulated comprehensive vistakons disposable contact lenses income longterm debt securities thecompany ability intent hold maturity carried amortized cost newaccounting pronouncements management determines appropriate classification invest recently adopted accounting pronouncements ment debt equity securities time purchase fiscal first quarter company adopted reevaluates determination balance sheet date financial accountingstandards board fasb guidance company periodically reviews investments equity securities amendments related criteria separating consideration impairment adjusts investments fair value inmultipledeliverable revenue arrangements theguidance decline market value deemed beother tempo aprovides principles application guidance whether multi rary losses securities considered beother ple deliverables exist arrangement separated temporary loss recognized earnings consideration allocated b requires entity allocate revenue arrangement using estimated selling prices deliver ables vendor nothave vendorspecific objective evidence thirdparty evidence selling price c eliminates use residual method requires entity allocate revenue usingthe relative selling price method theadoption amaterial impact companys results operations cash flowsor financial position however expanded disclosures multipledeliverable revenue arrangements notes consolidated financial statements property plant equipment depreciation reserves accounted accordance us gaap guidance property plant equipment stated cost thecompany revenue recognition right return exists sales return utilizes straightline methodof depreciation estimated reserves recorded full sales value sales returns con useful lives assets sumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices building building equipment years diagnostics segment typically resalable mate land leasehold improvements years rial thecompany rarely exchanges products inventory machinery equipment years returned products thesales returns reserve total company thecompany capitalizes certain computer software develop ranged annual sales customers ment costs included machinery andequipment incurred prior three fiscal reporting years inconnection developing obtaining computer software promotional programssuch product listing allowances internal use capitalized software costs amortized cooperative advertising arrangements recorded year estimated useful lives software generally range incurred continuingpromotional programs include coupons years volumebased sales incentive programs theredemption cost thecompany reviews longlived assets assess recoverability consumer coupons based historical redemption experience using undiscounted cash flows certain events changes product value volumebased incentive programs based operating economic conditions occur impairment assessment estimated sales volumes theincentive period may performed recoverability carrying value recorded products sold thecompany also earns service rev assets asset determined beimpaired loss enue copromotion certain products includes sales measured based difference assets fair value tocustomers thesearrangements evaluated determine andits carryingvalue quoted market prices available appropriate amounts bedeferred company estimate fair value using discounted value estimated future cash flows shipping andhandling shippingand handling costs incurred million mil revenue recognition lion million respectively thecompany recognizes revenue fromproduct sales included selling marketing administrative expense goods shipped delivered title risk loss pass amount revenue received shipping andhandlingis less customer provisions certain rebates sales incentives trade pro sales customers periods presented motions coupons product returns discounts customers accounted reductions sales thesame period related inventories sales recorded inventories stated lower cost market determined product discounts granted based terms arrange firstin firstout method ments direct indirect market participants well asmarket conditions includingprices charged competitors intangible assets goodwill rebates largest medicaid rebate provision esti theauthoritative literature us gaap requires goodwill mated based contractual terms historical experience trend andintangibleassets indefinite lives assessed annually analysis projected market conditions various markets impairment thecompany completed annual impairment test served thecompany evaluates market conditions products fiscalfourth quarter impairment deter groups products primarilythrough analysis wholesaler mined future impairment tests performedannually thirdparty sellthrough market research data well fiscal fourth quarter sooner triggering eventoccurs internally generated information intangible assets finite useful lives continue sales returns generally estimated recorded based amortized useful lives reviewed impairment historical sales returns information products exhibit warranted economic conditions see note unusual sales return patterns due dating competition details intangible assets goodwill marketing matters specifically investigated analyzed part accountingfor sales return accruals sales returns allowances financial instruments represent reserve products may returned due expira required us gaap derivative instruments recorded tion destruction field specific areas product recall thebalance sheet fair value changes fair value thereturns reserve based historical return trends product derivatives recorded period current earnings market percent gross sales accordance comprehensive income depending whether derivative companys accountingpolicies company generally issues credit designated part hedge transaction type customers returned goods thecompanys sales return hedge transaction johnson johnson annual reportthecompany documents relationships hedged contract development services notcentral companys items derivatives theoverall risk management strategy operations general incomestatement presentation includes reasons undertaking hedge transactions entering thesecollaborations follows derivatives theobjectives strategyare minimize naturetype collaboration statement earnings presentation foreign currency exposures impact companys financial thirdparty sale product sales customers performance protect companys cash flow fromadverse royaltiesmilestones paidto movements foreign exchange rates ensure appropriate collaborative partner ness financial instruments manage enterprise risk postregulatory approval cost goods sold associated financial institutions see note additional royalties received collaborative partner income expense net information financial instruments upfront payments milestones paid collaborative partner product liability preregulatory approval research development expense accruals product liability claims recorded undis research development payments counted basis probable liability incurred collaborative partner research development expense amount liability reasonably estimated based research development existing information theaccruals adjusted periodically payments received additional information becomes available result costand collaborative partner reduction research development expense availability factors effective november company milestonesare capitalized intangible assetsand amortized cost goods sold ceased purchasing thirdparty product liability insurance based usefullife availability prior coverage receivables insurance recover ies related product liability claims recorded undis advertising counted basis probablethat recovery realized costs associated advertising expensed year incurred included selling marketing administrative research development expenses advertising expenses worldwide comprised research development expenses expensed incurred television radio print media internetadvertising bil upfront milestone payments made thirdparties connec lion billion billion respectively tion research development collaborations expensed incurred point regulatory approval payments made income taxes third parties subsequent regulatory approval capitalized thecompany intends continue reinvest undistributed andamortized remaining useful life related product international earnings expand international operations amounts capitalized payments included fore us tax expense recorded respectto intangibles net accumulated amortization undistributed portion intended repatriation january thecompany enters collaborative arrangements typically january cumulative amount undistributed pharmaceutical biotechnology companies develop international earnings approximately billion commercialize drug candidates intellectual property billion respectively arrangements typically involve two parties active deferred incometaxes recognized tax consequences participants collaboration exposed significant risks oftemporary differences applying enacted statutory tax rates rewards dependenton commercial success activities applicable future years differences financial thesecollaborations usually involve various activities one reporting tax basis existing assets liabilities parties including research development marketing selling distribution often collaborations require upfront net earningsper share milestone royalty profit share payments contingentupon basic earnings per share computed dividing net earnings avail occurrence certain future events linked success asset able common shareholders weighted average number development amounts due fromcollaborative partners related common shares outstanding theperiod diluted earnings per development activities generally reflected reduction share reflects potential dilution thatcouldoccur securities research development expense performance exercised converted common stock using thetreasury stock method notes consolidated financial statements use estimates january current marketable securities consisted thepreparation consolidated financial statements conformity million million government securities accountingprinciples generally accepted us requires obligations corporate debtsecurities respectively management make estimates assumptions affect fair value government securities obligations corpo amounts reported estimates used accountingfor sales rate debtsecurities estimated using quoted broker prices discounts rebates allowances incentives product liabilities active markets incometaxes depreciation amortization employee benefits con thecompany invests excess cash deposits tingencies intangible asset liability valuations instance major banks throughout worldand highquality money determining annual pension postemployment benefit costs market instruments thecompany policy making company estimates rate return plan assets investments commercial institutions atleastan cost future health care benefits actual results may may equivalent credit rating differ thoseestimates company follows provisions us gaap record inventories ing litigation related contingencies liability recorded loss probable reasonably estimated best estimate end inventories comprised aloss within range accrued however estimate range dollars millions better minimum amount accrued raw materials supplies goods process annualclosing date finished goods thecompany follows conceptof fiscal year ends sunday nearest end month december normally total inventories fiscal year consists weeks every five sixyears fiscal year consists weeks case property plant equipment case end property plant equipment cost accumulated depreciation reclassification certain prior period amounts reclassified conform dollars millions current year presentation land land improvements buildings building equipment cash cash equivalents current machinery equipment marketable securities construction progress end amortized cost cash cash total property plant equipment gross equivalents current marketable securities comprised less accumulated depreciation total property plant equipment net amortizedcost dollars millions cash thecompany capitalizes interest expense part cost construction facilities equipment interest expense capital government securities obligations ized million million corporate debt securities million respectively money market funds depreciation expense including amortization capitalized time deposits interest billion billion total cash cash equivalents billion respectively current marketable securities upon retirement disposal property plant equip ment costs related amounts accumulated depreciation theestimated fair value amortized cost amortization eliminated asset accumulated ofjanuary theestimated fair value million depreciation accounts respectively thedifference asof january reflectinga million unrealized gain net asset value proceeds recorded earnings government securities obligations january current marketable securities consisted million million ofgovernment securities obligations corporate debtsecurities respectively johnson johnson annual report intangible assets goodwill fair value measurements end gross net amounts intangi thecompany uses forward exchange contracts manage expo ble assets sure variability cash flows primarily related foreign exchange rate changes future intercompany product third dollars millions party purchases ofraw materials denominated foreign currency intangible assets definite lives thecompany also uses cross currency interest rate swaps man patents trademarksgross age currency risk primarilyrelated borrowings types less accumulated amortization derivatives designated cash flow hedges thecompany also patents trademarksnet uses forward exchange contracts manage exposure vari intangiblesgross ability cash flows repatriation foreign dividends thesecon tracts designated net investment hedges additionally less accumulated amortization company uses forward exchange contracts offset exposure intangiblesnet certain foreign currency assets liabilities theseforward total intangible assets definite livesgross exchange contracts designated hedges therefore less accumulated amortization changes fair values derivatives recognized total intangible assets definite livesnet earnings thereby offsetting current earnings effect related foreign currency assets liabilities thecompany intangible assets indefinite lives enter derivative financial instruments trading specu trademarks lative purposes contain credit risk related contingent features purchased inprocess research development requirements post collateral ongoing basis company total intangible assets indefinite lives monitors counterparty credit ratings thecompany considers credit total intangible assetsnet nonperformance risk company enters agreements commercial institutions atleast purchased inprocess research development accounted asan indefinite lived intangible assetuntil underlying projectis completed orabandoned orequivalent credit rating january company hadnotional amounts outstandingfor forward foreign exchange goodwillas january january allocated contracts cross currency interest rate swaps billion segment business follows billion respectively derivative instruments berecorded balance med dev dollars millions consumer pharm diag total sheet fair value changes fair value derivatives goodwill december recorded period current earnings comprehensive income depending whether derivative designated part acquisitions ahedge transaction type hedge transaction currency translationother thedesignation cash flow hedge made entrance goodwill january date derivative contract inception derivatives acquisitions expected behighly effective changes fair value currency translationother derivative designated cash flow hedge highly goodwill atjanuary effective recorded accumulated comprehensive income includes reclassification segments underlyingtransaction affects earnings reclassified earnings account hedged transac theweighted average amortization periods patents tion gainslosses net investment hedges accounted trademarks intangible assets years years currency translation account insignificant respectively theamortization expense amortizable assets ongoing basis company assesses whether derivative million million million tax fiscal continues behighly effective offsetting changes cash years ended january january december flows hedged items derivative longer respectively certain patents intangible assets expected behighly effective hedge accounting discontinued written fair value fiscal years hedge ineffectiveness included current period earnings resulting charge included amortization expense income expense net material write downs material impact companys fiscal years ended january january refer results operations cash flows financial position note disclosures movements accumulated theestimated amortization expense thefive succeeding comprehensive income years approximates million tax per year substantially january balance deferred net gains amortization expense included cost products sold derivatives included accumulated comprehensive income million aftertax additional information seenote thecompany expects substantially amount related toforeign exchange contracts reclassified earnings next months result transactions expected occur thatperiod themaximum length time company hedging transaction exposure months excluding interest rate swaps theamount ultimately realized earnings differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative notes consolidated financial statements thefollowing table summary activity related designated derivatives fiscal years ended january january gainloss gainloss reclassified gainloss recognized accumulatedoci recognized cash flow hedges accumulated oci income incomeexpense dollars millions foreign exchange contracts foreign exchange contracts b b foreign exchange contracts c c cross currency interest rate swaps foreign exchange contracts e e total amounts shown table net tax effective portion ineffective portion aincluded sales customer bincluded cost products sold cincluded research development expense dincluded interest incomeinterest expense net eincluded incomeexpense net fiscal years ended january january loss currentspotforeign exchange rate thecompany million gain million respectively recognized believe fair values derivative instruments materially incomeexpense net relating foreign exchange differ amounts thatcouldbe realized upon settlementor contracts designated hedging instruments maturity changes fair value material effect fair value exit price wouldbe received sell thecompanys results operations cash flows financial posi asset paid transfer liability fair value marketbased tion thecompany also holds equity investments thatare classified measurement determined using assumptions level traded active exchange market market participants woulduse pricing asset liability thefollowing three levels inputs used measure authoritative literature establishes threelevel hierarchy priori fair value tize inputs used measuring fair value thelevels within level quoted prices active markets identical assets hierarchy described level highest andliabilities priority level lowest thefair value derivative financial instrument ie forward level significant observable inputs exchange contract currency swap aggregation currency level significant unobservable inputs future cash flows discounted present value prevailing market interest rates subsequently converted us dollar johnson johnson annual reportthecompanys significant financial assets liabilities measured fair value january january follows dollars millions level level level total total derivatives designated hedging instruments assets foreign exchange contracts cross currency interest rate swaps total liabilities foreign exchange contracts cross currency interest rate swaps total derivatives designated hedging instruments assets foreign exchange contracts liabilities foreign exchange contracts investments assets liabilities classified level exception investments millionwhich classified level includes million million noncurrent assetsfor fiscal years ending january january respectively includes million million noncurrent liabilities fiscal years ending january january respectively see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings thecompany access substantial sources funds thecomponents longterm debt follows numerous banks worldwide september company secured new day credit facility total credit available effective effective company approximates billion expires september dollars millions rate rate interest charged borrowings credit line agree debentures due ments based either bids provided banks prime rate debentures due london interbank offered rates libor plus applicable margins debentures due commitmentfees agreements material debentures due throughout company continuedto access notes due liquidity commercial paper market shortterm borrow b euro b euro ings andthe current portion longterm debt amounted approxi zero coupon convertible mately billion end billion subordinated debentures due borrowed commercial paper program theremainder debentures due represents principally local borrowing international subsidiaries debentures due company shelf registration securities notes due exchange commission enables company issue mm gbp timely basis debt securities warrants purchase debt securities mmgbp aggregate maturities longterm obligations commencingin notes due debenture due dollars millions notes due debentures due debentures due includes industrial revenue bonds less current portion weighted average effective rate translation rate january translation rate january excess fair value carrying valueof debt billion billion fair value noncurrentdebt estimated using market prices corroborated quoted broker prices activemarkets notes consolidated financial statements income taxes temporary differences carry forwards theprovision taxes incomeconsists follows dollars millions currently payable deferred tax deferred tax dollars millions asset liability asset liability us taxes employee related obligations international taxes stock based compensation total currently payable depreciation deferred nondeductible intangibles us taxes international rd capitalized international taxes tax total deferred reserves liabilities provision taxes income income reported tax purposes comparison incometax expense us statutory rate net operating loss companys effective taxrate carryforward international follows miscellaneous international miscellaneous us dollars millions total deferred income taxes us international thedifference net deferred tax incomeper bal earnings taxes income ance sheet net deferred tax included taxes tax rates incomeon balance sheet deferred tax miscellaneous us statutory rate us includes current year tax receivables thecompany ireland puerto rico operations whollyowned international subsidiary thathas cumulative net research orphan drug taxcredits losses thecompany believes likely us state local subsidiary realize future taxable incomesufficient utilize international subsidiaries excluding ireland deferred taxassets us manufacturing deduction thefollowing table summarizes activity related unrecog inprocess research nized tax benefits development iprd dollars millions us tax international income beginning year increases related current year tax positions effective tax rate increases related prior period tax positions decreases related prior period tax positions thecompany subsidiaries manufacturing ireland settlements incentive taxrate addition company subsidiaries operat lapse statute limitations ing puerto rico various tax incentive grants thedecrease end year thetax rate primarily due decreases taxable incomein higher tax jurisdictions relative taxable incomein lower thecompany billion billion billion unrec tax jurisdictions certain us tax adjustments thedecrease ognized tax benefits january january inthe tax rate primarily due increases taxable december respectively unrecognized tax bene incomein lower tax jurisdictions relative taxable incomein fits billion january ifrecognized wouldaffect highertax jurisdictions companys annual effective taxrate thecompany conducts busi ness files tax returns numerous countries currently tax audits progress number tax authorities theus internal revenue service irs completed audit tax years however limited number issues remaining open prior tax years goingback major jurisdictions company conducts business years remain open generally back year thecompany expect total amount unrecognized tax benefits significantly change next twelve months thecompany ableto provide reasonably reliable estimate timingof future tax payments relating uncertain tax positions johnson johnson annual reportthecompany classifies liabilities unrecognized tax benefits pensions benefit plans related interest penalties longterm liabilities interest thecompany sponsors various retirement pension plans expense penalties related unrecognized tax benefits includingdefined benefit defined contribution termination classified incometax expense thecompany recognized indemnity plans cover employees worldwide taxinterest million income million expense mil company also provides postretirement benefits primarily health lion expense respectively thetotal care us retired employees dependents amount accrued interest million million many international employees covered government respectively sponsored programs costto company significant retirement plan benefits primarily based employees compensation last three five years retirement employee related obligations number years service international subsidiaries end employee related obligations plans funds deposited trustees annuities recorded consolidated balance sheet purchased group contracts reserves provided thecompany fund retiree health care benefits dollars millions pension benefits advance right modifythese plans future thecompany uses date consolidated financial state postretirement benefits ments january january respectively postemployment benefits measurement date us international retirement deferred compensation benefit plans total employee obligations accordance us gaap company adopted less current benefits payable therecent standards related employers accountingfor defined employee related obligationsnoncurrent benefit pension postretirement plans prepaid employee related obligations million mil lion respectively included assets consolidated balance sheet net periodicbenefit costs thecompanys defined benefit retirement plans benefit plans include following components retirement plans benefitplans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements net periodic benefit cost thenet periodic benefit cost attributable us retirement plans million millionand million respectively notes consolidated financial statements amounts expected berecognized net periodic benefit cost life expectancy theamortization gains losses theother thecoming year thecompanys defined benefit retirement us benefit plans determined using corridor plans postretirement plans greater market value assets projected benefit obliga tion total unamortized gains losses excess corridor dollars millions amortized average remaining future service amortization net transition obligation prior service costsbenefits theus pension plans amortization net actuarial losses amortized remaining future service plan participants amortization prior service cost time plan amendment prior service costbenefit us benefit plans amortized average remaining unrecognized gains losses theus pension plans amor service full eligibility age plan participants time tized average remaining future service plan plan amendment plans active employees amortized average theweightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation theyear listed also net periodic benefit cost following year retirement plans benefitplans us benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels thecompanys discount rates determined consideringcur thefollowing table displays assumed health care cost trend rent yield curves representing high quality longterm fixed income rates individuals instruments theresulting discount rates consistentwith health care plans duration plan liabilities health care cost trend rate assumed next year theexpected longterm rate return plan assets assump rate cost trend rate assumed tion determined using building block approach considering declineultimate trend historical averages real returns asset class certain year rate reaches ultimate trend rate countries historical returns meaningful considera tion given local market expectations longterm returns onepercentagepoint change assumed health care cost trend rates wouldhave following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation johnson johnson annual reportthefollowing table sets forth information related thebenefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefitplans dollars millions change benefit obligation projected benefit obligationbeginning year service cost interest cost plan participant contributions amendments actuarial losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligationend year change plan assets plan assets fair valuebeginning year actual return plan assets company contributions plan participant contributions settlements benefits paid plan assets effect exchange rates plan assets fair valueend year funded status atend year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheetend year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligationsend year changes plan assets benefit obligations recognized comprehensive income net periodic benefit cost net actuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost credit effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company fund certain plans funding required billion billion projected benefit obligation billion billion underfunded status fiscalyears respectively relates unfunded pension plans billion billion ofthe accumulated benefit obligation fiscalyears respectively relate unfunded pension plans plans accumulated benefit obligations excess plan assets consist following retirement plans dollars millions accumulated benefit obligation projected benefit obligation plan assets fair value notes consolidated financial statements thefollowing table displays projected future benefitpayments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plansgross medicare rebates benefit plansnet benefit plan projected future benefitpayments international plans funded accordance local regula exclude million severance payments associated tions additional discretionary contributions made worldwide restructuring program deemed appropriate meet longterm obligations plans company contributed million mil certain plans funding common practice funding pro lion us international pension plans respectively vides economic benefit consequently company several thecompany plans continue fund us defined benefit pension plans funded plans comply pension protection act thefollowing table displays projected future minimum contributions companys us international unfunded retirement plans amounts include discretionary contributions thecompany may elect make future dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans pension plan overseen local committee board responsible theoverall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules andregulations local tax regulations availability investment vehicles separate accounts commingledaccounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds asset allocation equities fixed incomeis generally pursued unless local regulations andilliquidity require otherwise thecompanys retirement plan asset allocation end target allocations follows percent target plan assets allocation us retirement plans equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets thecompanys benefit plans unfunded except us life plan believes valuation methods appropriate insurance contract assets million million january consistent market participants use different january respectively methodologies assumptions determine fair value certain thefair value johnson johnson common stock directly financial instruments couldresult different estimate fair value held planassets million total plan assets reporting date atjanuary million total plan assets january valuationhierarchy theauthoritative literature establishes threelevel hierarchy determination fair value prioritize inputs used measuring fair value thelevels within theplan established welldocumented process hierarchy described table level determining fair values fair value based upon quoted market thehighestpriority level lowest prices available listed prices quotes available financial instruments categorization within valuation fair value based upon models primarily use inputs hierarchy based upon lowest level input significant marketbasedor independently sourced market parameters includ tothe fair value measurement ingyieldcurves interest rates volatilities equity debt prices foreign exchange rates credit curves johnson johnson annual reportfollowing description valuation methodologies used equity securitiescommon stocks valued closing theinvestments measured fair value price reported major market individual securi shortterm investmentscash quoted shortterm instru ties traded substantially common stock classified within ments valued closing price amount held deposit level valuation hierarchy custodian bank investments investment commingled fundstheinvestments public investment vehicles valued using net asset value nav provided vehicles valued using nav provided fund administrator administrator fund thenav based value thenav based value underlying assets owned underlyingassets owned fund minus liabilities fund minus liabilities divided number divided number shares outstanding thenav quoted shares outstanding assets level category quoted price market active classified level market price market active government agency securitiesa limited number insurance contractstheinstruments issued insurance investments valued closing price reported major companies thefair value based negotiated value market individual securities traded quoted underlyinginvestments held separate account portfolios well prices available active market investments classi considering thecredit worthiness issuer theunderlying fied within level valuation hierarchy quoted market prices investments government assetbacked fixed incomesecuri available thespecific security fair values esti ties general insurance contracts classified level mated using pricing models quoted prices securities sim quoted prices observable inputs pricing ilar characteristics discounted cash flows quoted market assetsother assets represented primarily limited prices security available active market partnerships real estate investments well commercial classified level loans commercial mortgages classified corporate debt instrumentsa limited number investments debt assets exchange listed actively traded valued closing price reported major market classified level inactively traded assets classified individual securities traded quoted prices avail level limited partnerships representinvestments private able active market investments classified level equity similar funds valued general partners quoted market prices available thespecific security well assets valued using unobservable inputs fair values estimated using pricing models quoted prices classified level securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs thefollowing table sets forth trust investments measured fair value january january quotedprices significant active significant markets observable unobservable identical assets inputs inputs level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets trust investments fair value notes consolidated financial statements level gains losses thetable sets forth summary changes fair value plans level assets theyears ended january january debt equity commingled insurance total dollars millions instruments securities funds contracts assets level balance december realized gains losses unrealized gains losses purchases sales issuances settlements net balance january realized gains losses unrealized gains losses purchases sales issuances settlements net balance january savings plan accumulated comprehensive income thecompany voluntary k savings plans designed components comprehensive incomeloss consist enhance existing retirement programs covering eligible employ thefollowing ees thecompany matches percentage employees total contributions consistent provisions plan gains accumulated heshe eligible total company matching contributions foreign gains losses plans million million million currency losses employee derivatives comprehensive dollars millions translation securities benefit plans hedges incomeloss respectively december changes capital treasury stock unrealized gain loss changes treasury stock net amount reclassed net earnings amounts millionsexcept treasury stock treasury stock net changes numberof shares thousands shares amount balance december december employee compensation stock option plans changes conversion subordinated debentures unrealized gain loss repurchase common stock net amount reclassed net earnings balance december net changes employee compensation stock option plans january conversion subordinated debentures changes repurchase common stock unrealized gain loss balance january net amount reclassed employee compensation stock option plans net earnings conversion subordinated debentures net changes repurchase common stock january balance january thetax effect unrealized gainslosses equity securi aggregate shares common stock issued approximately ties expense million incomeof million shares end expense million thetax effect related cash dividends paid per share compared toemployee benefit plans million million dividends per share per share million respectively thetax effect thegainslosses derivatives hedges expense million million million respectively see note additional information relating derivatives hedging thecurrency translation adjustments adjusted incometaxes relate permanentinvestments international subsidiaries johnson johnson annual report international currency translation common stock stock option plans stock translation subsidiaries operating nonus dollar cur compensation agreements rencies company determined local currencies january company stockbased compensation itsinternational subsidiaries functional currencies except plansthe shares outstandingare contracts companys highly inflationary economies defined stock option plan longterm incentive plan compound cumulative rates inflation nonemployee directors plan alza corporation ormore past three years substantial portion inverness medical technology inc scios inc stock option ofits cashflows local currency plans options restricted shares granted consolidatinginternational subsidiaries balance sheet cur plans exceptunder longterm rency effects recorded component accumulated incentive plan comprehensive income equity account includes results thecompensation cost charged income oftranslating balance sheet assets liabilities current plans million million million exchange rates except located highlyinflationary respectively thetotal incometax benefit economies thetranslation balance sheet accounts highly recognized incomestatement sharebased compensation inflationary economies reflected operating results costs million million million analysis changes respectively thetotal unrecognized compensation foreign currency translation adjustments included note cost million january million net currency transaction gains losses included january million december income expense losses million million theweighted average period costto berecognized million respectively years years years respectively sharebased compensation costs capitalized part ofinventory insignificant periods earnings per share thefollowing reconciliation basic net earnings per share stock options diluted net earnings per share fiscal years ended january stock options expire years fromthe date grant vest january december overservice periods range six months four years alloptions granted average high low prices millions except pershare data companys common stock thenew york stock exchange basic net earnings per share onthe date grant longterm incentive plan average shares company may issue million shares common stock outstanding basic shares available future grants longterm potential shares exercisable incentive plan million end stock option plans thecompany settles employee stock option exercises less shares repurchased treasury shares treasury shares replenished throughout treasury stock method year thenumber shares used settle employee stock convertible debt shares optionexercises adjusted average shares thefair value option award estimated date outstanding diluted grant using blackscholes option valuation model uses diluted net earnings per share assumptions noted following table expected volatility represents blended rate year daily historical average volatility thediluted net earnings per share calculation includes dilutive rate week average implied volatility rate based atthe effect convertible debt offset related reduction money traded johnson johnson options life years ininterest expense million aftertax years historical data isusedto determine expected life option theriskfree rate based us treasury yield curve diluted net earnings per share excludes million million effect time grant million shares underlying stock options theaverage fair value options granted respectively exercise price options respectively thefair value greater average market value wouldresult estimated based weighted average assumptions antidilutive effect diluted earnings per share riskfree rate rental expense lease commitments expected volatility rentals space vehicles manufacturing equipment office expected life yrs yrs yrs data processing equipment operating leases approxi dividendyield mately million million million respectively theapproximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year january dollars millions total commitments capital leases significant notes consolidated financial statements summary option activity plan january stock options exercisable january december january december changes average price average years ending dates presented lifeof years average price aggregate average life years respectively weighted aggregate outstanding average intrinsic value shares thousands shares exercise price dollars millions restrictedshareunits shares december thecompany grants restricted share units vesting period three years thecompany settles employee stock issuances options granted treasury shares treasury shares replenished throughout options exercised year thenumber shares used employee stock issuances options canceledforfeited summary share activity plan january shares december outstanding options granted shares thousands shares options exercised shares december options canceledforfeited granted shares january issued options granted canceledforfeited options exercised shares december options canceledforfeited granted shares january issued canceledforfeited total intrinsic valueof options exercised million shares january million million respectively granted thefollowing table summarizes stock options outstanding issued exercisable january canceledforfeited shares thousandsoutstanding exercisable shares january average average exercise average exercise exercise theaverage fair value restricted share units granted price range options life price options price respectively using fair market value date grant thefair value restricted share units discounted dividends paid restricted share units duringthe vesting period thefairvalue restricted share units settled million million million respectively average contractual life remaining years johnson johnson annual report segments businessand geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company customer represented total revenues amounts allocated segments include interest income expense noncontrolling interests general corporate income expense general corporate includes cash marketable securities includes million net litigation gain comprised million expensein thepharmaceutical segment gain million medical devices diagnostics segment includes million ofproduct liability expense comprised million pharmaceuticalsegment million medical devices diagnostics segment medical devices diagnostics segmentalso includes million expense cost associated thedepuy asrhip recall program includes million ofrestructuring expense comprised million millionand million forthe consumer pharmaceutical medical devices diagnostics segments respectively includes million fourth quarter net litigation gain comprised million expensein thepharmaceutical segment gain million medical devices diagnostics segment includes million million iprd forthe consumerand medical devicesand diagnostics segments respectively includes million fourth quarter net litigation gain comprised million expense consumer segment gain million medical devices diagnostics segment medical devices diagnostics segment also includes million gain thedivestiture theprofessional wound care business ethicon inc longlived assetsinclude property plant equipment net respectively intangible assetsand goodwill netfor respectively notes consolidated financial statements selected quarterly financial data unaudited selected unaudited quarterly financial data theyears summarized first second third fourth first second third fourth dollars millions except pershare data quarter quarter quarter quarter quarter quarter quarter quarter segmentsales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share firstquarter includes million aftertaxof income net litigation second quarter includes million aftertaxof income net litigation fourth quarter includes aftertax charge million net litigation settlements aftertax charge million product liability expense aftertax charge million cost associated thedepuy asrhip recall program fourth quarterof includes aftertax charge millionfor restructuring million aftertaxof income net litigation business combinations divestitures theiprd related acquisition micrus endovascular certain businesses acquired million cash corporation million associated ischemic million liabilities assumed acquisitions flow diverter technologies thevalue iprd calculated accounted purchase method accordingly using cash flow projections discounted therisk inherent results operations included financial statements projects probability success factors ranging respective dates acquisition used reflectinherent clinical regulatory risk thediscount theacquisitions included acclarent inc privately held rate applied medical technology company dedicated designing developing company announced agreement commercializing devices address conditions affecting acquire outstanding equity crucell nv already ear nose throatent respivert ltd privately held drug dis approximately billion cash tender offer covery company focused developing smallmolecule inhaled january company held approximately crucells therapies thetreatment pulmonary diseases micrus outstandingordinaryshares crucell global biopharmaceutical endovascular corporation global developer manufacturer company focused research development production minimally invasive devices hemorrhagic ischemic stroke marketing vaccines antibodies infectious disease excess purchase price estimated fair valueof worldwide february company announced tangibleassets acquired amounted million tender offer crucell completed declared assigned identifiable intangible assets residual recorded offer unconditional goodwill amount approximately million certain businesses acquired million cash identified valueof iprd associated acquisitions million liabilities assumed noncontrolling interests acclarent inc respivert ltd micrus endovascular corporation acquisitions accounted theiprd related acquisition acclarent inc purchase method accordingly results operations million associated novel endoscopic catheter included financial statements respective dates based devices meet needs ent patients thevalue ofacquisition iprd calculated using cash flow projections discounted acquisitions included mentor corporation leading risk inherentin projects probability success factors supplier medical products global aesthetics market ranging used reflectinherent clinical cougar biotechnology inc development stage biopharmaceutical regulatory risk thediscount rate applied company specific focus oncology finsbury orthopaedics theiprd related acquisition respivert ltd limited privately held ukbased manufacturer global distrib million associated narrow spectrum kinase utor orthopaedic implants gloster europe privately held inhibitors unique profileof antiinflammatory activities developer innovative disinfection processes technologies treatments moderate severe asthma chronic obstructive prevent healthcareacquired infections substantially pulmonary disease copd cystic fibrosis cf thevalue assets rights elans alzheimers immunotherapy program iprd calculated using cash flow projections discounted newly formed company company owns therisk inherentin projects probability success factors elan owns ranging used reflectinherent clinical regulatory risk thediscount rate applied johnson johnson annual reporttheexcess purchase price estimated fair value theexcess purchase price estimated fair value tangible assets acquired amounted million andhas tangible assets acquired amounted million assigned identifiable intangibleassets residual recorded assigned identifiable intangibleassets residual recorded goodwill amount approximately million goodwill approximately million identified identified value iprd primarily associated value iprd associated acquisitions omrix biophar acquisitions cougar biotechnology inc substantially maceuticals inc amic ab surgrx inc healthmedia inc assets rights elans alzheimers immunotherapy program theiprd charge related acquisition omrix biophar additionally approximately million identified maceuticals inc million associated stand value intangible assets including patents technology alone combination biosurgical technologies used achieve customer relationships primarily associated acquisition hemostasis thevalue iprd calculated using cash flow mentor corporation projections discounted therisk inherentin projects iprd related acquisition cougar biotechnology probability success factors ranging used inc million associated abiraterone acetate reflectinherent clinical regulatory risk thediscount rate late stage firstinclass compound treatment prostate applied cer valueof iprd calculated using cash flow projec theiprd charge related acquisition amic ab tions discounted risk inherent projects probability million associated pointofcare device cast success factors ranging used reflect inherent chip technologies thevalue iprd calculated using clinical regulatory risk discount rate applied cash flow projections discounted therisk inherent company acquired substantially projects thediscount rate applied assets rights elans alzheimers immunotherapy program theiprd charge related acquisition surgrx inc newly formed company janssen alzheimer immunother million associated vessel cutting sealing surgical apy jai company owns elan owns devices thevalue iprd calculated using cash flow pro addition company purchased approximately million jections discounted therisk inherentin projects probability newly issued american depositary receipts adrs elan repre success factors ranging used reflectinher senting elans outstanding ordinaryshares aspart ent clinical regulatory risk thediscount rate applied transaction company paid million elan committed theiprd charge related acquisition healthmedia fundup million elans share research develop inc million associated primarily process ment spending jai total consideration million enhancements software technology thevalue iprd million represents fair value investment wascalculated using cash flow projections discounted therisk elan based elans share price actively traded market inherentin projects aprobability success factor date transaction theiprd related transaction used reflectinherentrisk thediscount rate applied million associated bapineuzumab potential supplemental pro forma information firstinclass treatment thatis beingevaluated slowing pro accordance us gaap standards related business combi gression alzheimers disease thevalue iprd calcu nations goodwill intangible assets provided lated using cash flow projections discounted therisk inherentin asthe impact aforementioned acquisitions projects probability success factors ranging material effect companys results operations cash flows used reflectinherent clinical regulatory risk thedis financial position count rate applied thenoncontrolling interest related exception divestiture breast care transaction million company recorded business ethicon endosurgery inc thegain recorded noncurrent liabilities income expense divestiture profes certain businesses acquired million cash sional wound care business ethicon inc resulted million ofliabilities assumed acquisitions gainof million tax recorded income accounted purchase method accordingly expense net divestitures results operations included financial statements material effect companys results operations cash respective dates acquisition flows financial position acquisitions included amic ab privately held swedish developer vitro diagnostic technologies use pointofcare nearpatient settings beijing dabao cosmetics co ltd acompany sells personal care brands china surgrx inc privately held developer advanced bipolar tissue sealing system used ensealfamily devices healthmedia inc privately held company creates webbased behavior change interventions lge performance systems inc privately held company known human performance institute develops sciencebased training programs improve employee engagement productivity omrix biopharmaceuti cals inc afully integrated biopharmaceutical company devel ops markets biosurgical andimmunotherapy products notes consolidated financial statements legal proceedings company posttrialmotions challenging verdictwill product liability filed unsuccessful followed appeal thecom thecompanys subsidiaries involved numerous product pany believes strong arguments supporting appeal liability cases united states many concern alleged thecompany believes potential unfavorable adverse reactions drugs andmedical devices thedamages comeis probable therefore established reserve claimed substantial company confident respectto verdictin commonwealth pennsylvania suit adequacy warnings instructions usethat accompany janssen trial commenced june thejudge dis products feasible predictthe ultimate outcomeof missed case close plaintiffs evidence thecom litigation thecompany established product liability reserves monwealth filed posttrialmotions pending based currently available information somecases may cases scheduled trial south carolina currently scheduled limited changes reserves may required future march texas scheduled june additional information becomes available august depuy orthopaedics inc depuy announced multiple products johnson johnson subsidiaries sub worldwide voluntary recall asrxlacetabular system jectto numerous product liability claims lawsuits anddepuyasrhip resurfacing system used hip replacement significant number claimants pending lawsuits surgery claims personal injury made claims regarding injuries allegedly due ortho evra company thecompany received limited information date risperdal levaquin duragesic charitartificial respectto potential claims costs associated disc cypherstent asrhip theseclaimants seek sub recall thecompanys product liability reserve increased stantial compensatory available punitive damages part due anticipated product liability expense costs associ respectto risperdal attorneys general multi ated depuyasrhip recall however point time ple states office general counsel commonwealth thecompany estimate range reasonably possible pennsylvania filed actions seeking reimbursement medic losses respect matter changes reserve may aid public funds risperdalprescriptions written required future additional information becomes available offlabel use compensation treating citizens alleged adverse reactions risperdal civil fines penalties damages patent litigation overpayments state others punitive damages theproducts various johnson johnson subsidiaries relief theattorney general texas joined qui tam subject various patent lawsuits outcomes could action state seeking similar relief certain actions potentially adversely affect ability subsidiaries also seek injunctive relief relating promotion risperdal sellthose products require payment past damages theattorneys general approximately states indi future royalties cated potential interest pursuing similar litigation january cordis corporation cordis settled companys subsidiary janssen pharmaceutica inc janssen patent infringement action boston scientific corporation orthomcneiljanssen pharmaceuticals inc omjpi boston scientific delaware federal district court accusing obtained tolling agreement staying running statute express taxusand libertestents infringing palmaz limitations pursue coordinated civil investigation gray patents terms settlement boston scientific omjpi regarding potential consumer fraud actions connection dropped lawsuit cordis cypherstent foundto marketing risperdal addition six cases infringed jang patent paid cordis billion feb filed union health plans seeking damages alleged overpay ruary boston scientific also agreed pay cordis addi ments risperdal several seek certification class tional million plus interest january august actions one dismissed summary judgment boston scientific paid full million plus interest inthe casebroughtby attorney general west virginia based company recorded billion thefiscal first quarter claims alleged consumer fraud duragesicas well cordis granted boston scientific worldwide license risperdal janssen omjpi foundliable damages palmaz gray patents boston scientific granted cordis assessed million omjpi filed appeal thewest vir worldwide license jang patents stents sold ginia supreme court accepted janssens appeal judgment cordis exceptthe mm size cypher appeal argued september october cordis several pending lawsuits new jersey west virginia supreme court unanimously reversed trial courts delaware federal district courts guidant corporation decision december attorney general dismissed guidant abbott laboratories inc abbott boston scientific case related risperdalwithout payment thereafter andmedtronic ave inc medtronic allegingthat xience v company settled case insofar related duragesic abbott promusboston scientific endeavormedtronic september october falseclaimsuitbrought drug eluting stents infringe several patents owned licensed louisiana statute tried jury returned verdict mil cordis january one cases boston lion favor states attorney general janssen scientific alleging sales promusstent infringed johnson johnson annual reportwright falotico patentsthe district court delaware found infringed entered judgment jjvc jjvc appealed wrightfalotico patentinvalid lack written description judgment court appeals thefederal circuit april andor lack enablement cordis appealed ruling district court denied cibas motion permanently january jury eastern districtof texas returned enjoin infringing lenses ciba appealed ruling appeal verdictfinding cordis sales cypherstent willfully consolidated jjvcs appeal merits ciba brought infringed patentissued plaintiff bruce saffran saffran v cordis suit jjvc counterparts nicholson patents ed tx thejury awarded plaintiff million cordis various european countries netherlands andfrance alleged thatplaintiffs patent invalid unenforceable patents found valid infringed jjvc enjoined doctrine inequitable conduct abench trial issue selling oasys decisions appealed france expected take place march unsuccessful appeal denied netherlands appeal pending defense company seek overturn verdictthrough cibas patents foundto beinvalid germany uk posttrialmotions appeal necessary since company austria cibaappealed decisions january believes potential unfavorable outcomeis proba parties settled pending lawsuits appeals contact lens ble established reserve respectto case field worldwide entered crosslicenses various patents october tyco healthcare group lp tyco us pertinent contact lens fieldincluding nicholson patents surgical corporation sued ethicon endosurgery inc ees alleging theinjunctions france netherlands lifted several features eess harmonic scalpel infringed four tyco may abbott biotechnology ltd abbott filed patents inoctober court granted part denied patent infringement lawsuit centocor cobi part crossmotions summary judgment result opin united states district court thedistrict massachusetts ion number claims found invalid number suit alleges centocors simponiproduct human antitnf found infringed claim found valid infringed alpha antibody infringes abbotts patent salfeld patent trialcommenced december court dismissed thecasewas stayed pending resolution arbitration filed case without prejudice grounds tyco notown centocor directed claim thatit licensed patents suit thedismissal without prejudice affirmed patent june arbitrator ruled thatcentocor appeal january tyco filed another complaint district license patentsinsuit thematter proceed connecticut asserting three four patents previous district court massachusetts issues infringement suit adding new products caseis scheduled betried validity abbott patents october august abbott gmbh co abbott gmbh may centocor inc centocor ortho biotech inc abbott bioresearch center filed apatent infringement lawsuit cobi filed lawsuit genentech inc genentech centocor cobi united states district court usdistrict court thecentral district california seekingto forthe district massachusetts thesuit alleges cobis invalidate cabillyii patent prior filing suit cobi stelaraproduct infringes two us patents assigned abbott sublicense patent celltech licensed gmbh august cobifiled complaint declaratory bygenentech remicadeand paying royalties judgment noninfringement invalidity abbott gmbh tocelltech cobihas terminated sublicense stopped patents united states district court thedistrict paying royalties genentech filed acounterclaim alleging columbia date also united states district court thatremicadeinfringes cabilly ii patents genentech thedistrict columbia cobi filed complaint review droppedall claims manufacture remicade patent interference decision granting priority invention one stelara simponiand reoproalso infringes one ofthe two asserted patents abbott gmbh august patents relating thepurification antibodies made abbott gmbhand abbott laboratories limited brought patent recombinant dnatechniques thecourt conducted hearing infringement suit thefederal court canada alleging summary judgment motions august shortly thereafter stelarainfringes abbott gmbhs canadian patent theparties settled case cobi receiving license canadian case scheduled betried october thecases cabilly ii patent filed cobi district columbia transferred january genentech initiated arbitration district massachusetts discovery case ongoing celltech seeking damages allegedly cooperating cobi august bayer healthcare llc bayer filed suit toimproperly terminate prior agreement cobiwas cobi massachusetts district court alleging infringement sublicensed cabilly patents cobi indemnity cobis simponiproduct patent relating human anti agreement celltech celltech asserted cobi tnf antibodies january court issued judgment dis liable damages celltech may required pay genentech missing bayers infringement claims bayer may appeal ruling arbitration innovember bayer also filed suit european counter april bench trial held federal district part patents germany netherlands thecourt court middle district florida liability phase ciba inthe netherlands held dutch patentinvalid parallel case vision corporations ciba patent infringement lawsuit alleging bayer broughtagainst abbott thedutch court subsequently johnson johnson vision care incs jjvc acuvue entered judgment favor european centocor affiliate oasyslenses infringe three nicholson patents august bayer appealed judgment netherlands theinfringement district court foundtwo thesepatents valid trial germany scheduled begin august notes consolidated financial statements june centocors cobi lawsuit alleging billion inclusive interest entered favor centocor abbotts humiraantitnf alpha product infringes centocors december abbott filed appeal court appeals patent went trial federal district court eastern dis thefederal circuittherefore company reflected trict texas june jury returned verdict finding billion consolidated financial statements theoral patent valid willfully infringed awarded centocor damages argumenton appeal held november december approximately billion bench trial abbotts defenses centocor also filed new lawsuit eastern district ofinequitableconductand prosecution laches held august texas seeking damages infringement patent attribut district court decided issues favor cento able sales humirasubsequent jury verdictin june cor abbotts post trial motions denied except february court appeals reversed june district court granted abbotts motion overturn jury decision billion judgement district court finding willfulness judgment amount approximately thefollowing chart summarizes various patent lawsuits concerning products companys subsidiaries yet proceedtotrial jj plaintiff product company patents patent holder court trialdate date filed cypherstent cordis wall wall ed tx q cypherstent cordis saffran saffran ed tx trial concluded blood glucose meters strips lifescan wilsey roche diagnostics de simponi centocorcobi salfeld abbott laboratories simponi centocorcobi boyle bayer healthcare stelara centocorcobi salfeld abbott gmbh trial date scheduled q reflects companys fiscal quarter summary judgment granted litigation filers ofabbreviated new drug noninfringement invalidity unenforceability patents applications andas event subsidiary company involved success thefollowing chart indicates lawsuits pending generic firms ful actions statutory month stay expires filed abbreviated new drug applications andas seeking aruling district court obtained firms involved tomarket generic forms products sold various subsidiaries ability upon fda approval introduce generic versions company prior expiration applicable patents covering ofthe product issue resulting substantial market share products theseandas typically include allegations andrevenue losses theproduct companys subsidiary noted following chart month stays expired expire respectto anda challenges regarding various products brand name patentnda generic trial date month product holder challenger court date filed stay expiration concerta orthomcneiljanssen andrx de q none mg controlled alza kudco de release tablet impax teva de levaquin mg tablet orthomcneil lupin nj ortho tricyclenlo orthomcneil watson nj mg mg mg mg sandoz nj mg mg lupin nj mylan nj ultram er mg tablet orthomcneilbiovail par de q ultram er mg tablet orthomcneilbiovail impax de ultram er mg tablet orthomcneilbiovail paddock mn ultram er mg tablet orthomcneilbiovail cipher de ultram er mg tablet orthomcneilbiovail lupin de prezista tibotec mylan nj tibotec lupin nj trial date scheduled q reflects companys fiscal quarter johnson johnson annual reportin october companys subsidiary orthomcneil ultrameractions orthomcneil inc omjpi janssen pharmaceuticals inc omjpi filed suitin federal district filed lawsuits different dosages us district court court new jersey watson laboratories inc watson delaware par pharmaceuticals inc par pharmaceuti response watsons anda regarding ortho tricyclenlo cals companies inc par may june october two june omjpi filed suit federal district court new tramadol erformulation patents owned purdue pharma prod jersey sandoz laboratories inc sandoz response ucts lp purdue napp pharmaceutical group ltd napp sandozs anda regarding ortho tricyclenlo thesandoz omjpi also filed lawsuits different dosages impax watson cases consolidated september laboratories inc impax tramadol er formulation patent omjpi entered asettlement agreement sandoz owned purdue napp august november purdue january thecompanys subsidiary omjpi filed suit napp biovail laboratories international srl biovail nda federal district court new jersey lupin ltd lupin holder joined coplaintiffs inthe lawsuits par impax pharmaceuticals inc collectively lupin response lupins biovail omjpi subsequently dismissed lack anda regarding ortho tricyclenlo lupin case standing thetrial par took place april august consolidated watson case discussed november court issued decision finding patentsinsuit invalid thecompanys subsidiary omjpifiled suit federal district purdue appealed decision november case court new jersey mylan inc mylan pharmaceuticals impax stayed consent parties septem inc collectively mylan famy care ltd response famy ber october respectively purdue filed suits cares anda regarding ortho tricyclenlo paddock laboratories inc paddock cipher pharmaceuticals action mcneilppc inc mcneilppc alza cor inc cipher tramadol er formulation patents june poration alza andrx corporation andrx respect federal circuit court affirmed district courts decision anda challenge concertapatents fiveday nonjury parcase thecaseagainst cipher impax paddock dis trial held federal district court delaware december missed based collateral estoppel effect par decision march court ruled one concertapatent january purdue filed suit lupin ltd would infringed andrxs proposed generic product tramadol er formulation patents thepatent invalidbecause itwas notenabled court dis november thecompanys subsidiary tibotec inc missed without prejudice andrxs declaratory judgment suit sec tibotec filed suit federal district court new jersey ond patent lack jurisdiction mcneilppc alza filed lupin ltd lupin pharmaceuticals inc collectively lupin mylan appeal may appeals court heard argument february inc mylan pharmaceuticals inc collectively mylan response april court appeals affirmed judg lupins mylans respective andas regardingprezista ment district court patent invalidbecause january tibotec inc tibotec received paragraph iv enabled court reach issue infringement notification fromteva pharmaceuticals inc advising teva january alza omjpi filed suit federal district filed ananda seeking approval market generic prezista court delaware kremersurban llc kudco ireland product expiration certain patents owned licensed ltd kudco response kudcos anda challenge regarding tibotec tibotec evaluating notification concertatablets notice letter kudco contends two alza patents concertaare invalid infringed general litigation kudco generic one patent since dropped case september plaintiffs employment discrimination november alza omjpi filed suit federal litigation initiated company federal district district court delaware impax laboratories inc teva court new jersey moved certify class african american pharmaceuticals usa incand teva pharmaceutical industries ltd hispanic salaried employees company affiliates response notice impaxthat itmade major amendment us employed time november anda respectto mgdosegeneric version present plaintiffs seek monetary damages theperiod concerta notice letter describing major amendment present including punitive damages equitable impax contends thata concertapatent invalid relief thecourt denied plaintiffs class certification motion infringed proposed generic version december motion reconsideration april action lupin pharmaceuticals inc lupin plaintiffs sought appeal decisions april regarding anda concerning levaquin lupin contended court appeals ruled plaintiffs appeal denial class us patent trademark office improperly granted patent certification untimely july plaintiffs filed motion term extension patentthatorthomcneil inc ortho certification modified class company opposed mcneiljanssen pharmaceuticals inc omjpi licenses districtcourt denied plaintiffs motion july court daiichi pharmaceuticals inc daiichi lupin alleged theactive ofappeals denied plaintiffs request leave appeal denial ingredientin levaquinwas subject prior marketing ofcertification modified class thecompany continue therefore eligible thepatent term extension lupin con defend plaintiffs individual claims discrimination ceded validity product wouldviolate patent mar september centocor ortho biotech products lp keted prior expiration original patent term summary coblp intervened inventorship dispute kansas judgment lupin granted may lupin university center research kucr involving certain us appealed oral argument held september may governmentowned velcadeformulation patents kucr brought court appeals affirmed judgment trial court action us government district kansas seek favor orthomcneil omjpi daiichi patent ing add two kansas university scientists patents us term extension covering levaquinlevofloxacin valid government licensed patents foreign counterparts thereafter lupin requested rehearing en banc denied tomillennium pharmaceuticals inc mpi turn sublicensed notes consolidated financial statements thepatents foreigncounterparts cobi commercial federal court consolidated pretrial purposes marketing outside us kucr succeeds coinventorship multidistrict litigation mdl federal district court boston claim establishes coownership us velcadeformula massachusetts plaintiffs cases include classes pri tion patents potential issue arise vate persons entities paid portionof purchase respect foreigncounterparts thepatents kucr suc thedrugs issue based awp state government entities cessful may adversely affect cobis license rights inthose coun made medicaid payments drugs issue based awp triesin may parties reached agreement resolve themdl court identified classes massachusettsonly pri disputes case submit inventorship issue arbitra vate insurers providing medigap insurance coverage private tion andthe casehas stayed pending arbitration ifkucr payers physicianadministered drugs payments wins arbitration parties request court issue based awp class class national class order correct inventorship relevantpatents us individuals made copayments physicianadministered government cobi mpi prevailthe case dismissed drugs covered medicare class trial two massachu withprejudice settsonly class actions concludedbefore mdl court decem february basilea pharmaceutica ag basilea brought ber june mdl court issued posttrialrulings arbitration johnson johnson johnson johnson dismissing johnson johnson defendants caseregard pharmaceutical research development llc cilag gmbh ingall claims classes subsequently class well international alleging company breached license plaintiffs appealed class judgment september agreement ceftobiprole among things failing secure court appeals vacated judgmentand remanded fda approval csssi skin indication allegedly failing proceedings districtcourt thejohnson johnson properly develop pneumonia indication november defendants filed motion summary judgment regard arbitration panel issued decision company satisfied class district court granted part denied damages award part subsequently johnson johnson defendants filed may cobi commenced arbitration proceeding motion challenging adequacy plaintiffs proposed class american arbitration association scheringplough representative pending corporation subsidiaryscheringplough ireland company awp cases broughtby various attorneys general pro collectively scheringploughcobi scheringplough ceeded trial manufacturers three state cases parties series agreements distribution agreements certain companys subsidiaries set grant scheringplough exclusive right distribute drugs trialidaho october kentucky january remicadeand simponiworldwide exceptwithin united kansasinmarch state cases likely beset states japan taiwan indonesia peoples republic trialin thecoming year addition awp case chinaincluding hong kong territory cobi distributes johnson johnson defendants broughtby state pennsylvania remicadeand simponi next generation treatment within tried commonwealth court october november united states arbitration cobi seeks declaration thecourt found states favor regard certain agreement merger merck co inc merckand claims pennsylvania unfair trade practices consumer scheringplough constitutes change control theterms protection law entered injunction awarded million distribution agreements permits cobi terminate restitution million civil penalties thecourt found agreements thetermination distribution agreements would johnson johnson defendants favor thestates claims unjust return cobi right distribute remicadeand simponi enrichment misrepresentationfraud civil conspiracy within territory scheringplough filed response cobis certain states claims pennsylvania unfair trade arbitration demand denies undergone change practices consumer protection law theparties currently control thearbitrators selected evidentiary portion engaged post trialbriefing followed appeal hearing concluded october oral argument tothe pennsylvania supreme court ifnecessary thecompany held late decision expected first half believes strong arguments supporting appeal december state israel sheba medical center company believes potential unfavorable outcome filed suit district court tel aviv jaffa various omrix isnot probable therefore established reserve affiliates lawsuit state claims employee respectto verdict governmentowned hospital inventor several patents april lawsuit filed united states district related fibrin glue technology developed court thenorthern district california company government employee thestate claims right omnicare inc unidentified companies individuals transfer intellectual property omrix belongs company filed motion dismiss plaintiffs filed amended state thestate seeking damages plus royalty quixiland complaint theamended complaint asserts defendants evicelor alternatively transfer patents state engaged unlawful trying arrangement violation sher man act california business professions code average wholesale priceawplitigation amended complaint also asserted claims unjust enrichment company several pharmaceutical subsidiaries along civil conspiracy thecompany moved dismiss amended com numerous pharmaceutical companies defendants plaint january court granted companys motion aseries lawsuits state federal courts involving allegations dismiss causes action amended complaint pricing marketing certain pharmaceutical products granted plaintiffs leave filean amended complaint amounted fraudulent otherwise actionable conduct johnson johnson named nominal defendant among thingsthecompanies allegedly reported inflated six shareholder derivative lawsuits us district court average wholesale price awp drugs issue many district new jersey behalf company shareholders thesecases federal actions andstate actions removed certain current former directors officers company johnson johnson annual reportderivatively behalf company calamore v coleman et al inaddition settlement included civil payment part filed april carpenters pension fund west virginia v paid federal government part paid weldon et al filed may feldman v coleman et al filed set aside payment tostates medicaidprograms may hawaii laborers pension fund v weldon et al filed january janssenpharmaceutica incnow omjpi may ryan v weldon et al filed june min received subpoena office inspectorgeneral neapolis firefighters relief association necaibew pension trust us office personnel management seeking documents concerning fund necaibew welfare trust fund v weldon et al filed sales marketingof payments physicians connec june theseactions consolidated august tion salesandmarketingof clinical trials risperdal onelawsuit johnson johnson shareholder derivative risperidone documents subsequent litigation amended consolidated complaint filed also requested additional subpoenaseeking informa december additional derivative suit filed us tion marketingofand adverse reactions risperdalwas district court thedistrict new jersey december received us attorneys office forthe eastern districtof copeland v mulcahy et al lawsuit consolidated pennsylvania innovember subpoenas seeking testimony johnson johnson shareholder derivative litigation addi various witnesses grand jury also received tionally johnson johnson named nominal defendant janssen cooperating responding ongoing requests fordocu shareholder derivative lawsuit new jersey superior court ments witnesses government continuing actively behalf company shareholders certain current former investigate matter february governmentserved civil directors officers company derivatively behalf investigative demands seeking additional information relating company wolin v johnson johnson filed september sales marketing risperdaland sales marketingof theparties wolin action stipulated wolin invega focus matters alleged promotion action shall stayed johnson johnson shareholder risperdaland invegaforofflabel uses government derivative litigation completely resolved theseshare notified company pending qui tam actions alleging holder derivative actions similar claims collectively offlabel promotion risperdal discussions ongoing assert variety alleged breaches fiduciary duties including effort resolve potential criminaland civil claims arisingfrom among things defendants allegedly engaged matters whether resolution reached terms approved failed remedy prevent defective medical uncertain loss probable respectto matter devices improper pharmaceutical rebates improper offlabel mar company unable estimate potential loss time ulti keting pharmaceutical medical device products violations mate resolution ofthese matters expected havea material current good manufacturing practice regulations resulted adverse effecton companys financial position although res product recalls failed disclose theaforementioned alleged olution reporting period could material impacton misconduct companys filings securities exchange companys results operationsand cash flows forthat period act complaint seeks variety relief including september ortho biotech inc nowcobi received monetary damages corporate governance reforms asubpoenafrom us office inspector generals denver july complaint filed shareholder colorado field office seeking documents directed sales company new jersey superior court chancery division middle marketing procritepoetin alfa tothe present sex county lipschutz v johnson johnson seeking compel well dealings us oncology inc healthcare services inspection company books records respectto certain network oncologists cobi responded subpoena product recalls various manufacturing plants lawsuit november attorney general common dismissed october wealth massachusetts issued civil investigative demand depuy orthopaedics inc depuy seeking information regarding financial relationships number massachusettsbased july centocor cobi received request volun orthopedic surgeons providers depuy orthopaedics inc tarily provide documents information criminal division depuy responded massachusetts additional requests ofthe us attorneys office districtof new jersey connection july scios inc scios received subpoena investigation various centocor marketing practices usattorneys office district massachusetts seeking documents subsequentrequests documents received related sales marketing natrecor scios responded us attorneys office company centocor subpoena early august scios wasadvised responded requests documents information investigation would handled us attorneys office december orthomcneil pharmaceutical inc northern district california san francisco additional requests omjpi received subpoena us attorneys office documents received responded former scios boston massachusetts seeking documents relating market employees testified grand jury san francisco ing includingalleged offlabel marketing drug topamax quitam complaints unsealed february us topiramate fiscal second quarter omjpi entered government intervened one qui tam actions filed asettlement agreement resolving federal governments acomplaint sciosand company june scios investigation one part thesettlement orthomcneil pharma johnson johnson filed motion dismiss qui tam complaint ceutical llc subsidiary ofomjpi pled guilty single mis filed government motion wasdeniedthe criminal demeanor violation food drugand cosmetic act paid investigation continuing discussions underway effort acriminal fine omjpi denies engaged wrongful conduct settle matter whether settlement reached beyond acknowledging limited conduct orthomcneil terms isuncertain pharmaceutical llc basis ofthe misdemeanor plea notes consolidated financial statements september company received subpoena may new york state attorney general issued us attorneys office districtof massachusetts seeking docu subpoena seeking information relating marketing safety ments related sales marketing eight drugs omnicare procrit thecompany responded requests inc omnicare manager pharmaceutical benefits long april company received two subpoenas term care facilities thecompanys subsidiaries involved responded office attorney general state delaware thesub subpoena several employees companys pharmaceuti poenas seek documents information relating nominal pricing cal subsidiaries subpoenaed testifybefore grand jury agreements purposes subpoenas nominal pricing agree connection investigation april company ments defined agreements company agreed wasserved complaints two civil qui tam cases related provide pharmaceutical product less ten percentof marketing prescription drugs omnicare january average manufacturer price theproduct thecompany government filed complaint intervening cases responded requests complaint asserts claims federal false claims act march company received letter request related state law claim connection marketing several attorney general state michigan therequest seeks drugs omnicare thecomplaints allege johnson johnson documents information relating nominal price transactions provided omnicare rebates alleged kickbacks thecompany responded request caused omnicare filefalse claims medicaid june company received subpoena government programs subsequently commonwealth united states attorneys office thedistrict massachusetts massachusetts virginia kentucky states california relating marketing biliary stents companys cordis indiana intervened action thecompanys motion dis subsidiary cordis cooperating responding subpoena miss governments relators complaints governments afalse claims act complaint filed dallas relating similar relators oppositions companys reply brief issues theus department justice several states filed hearing companys motion dismiss held declined intervene time motion dismiss texas october thecourt ruled motion quitam case pending november lawsuit filed seal april company received hippa subpoena fromthe company along codefendants mckesson corporation us attorneys office district massachusetts boston seek omnicare inc former employee united states district ing information regarding companys financial relationship court eastern district pennsylvania united states ex rel several psychiatrists company responded request scott bartz v ortho mcneil pharmaceutical incet al investi april orthoclinical diagnostics inc ocd received gation united states declined intervene thecasewas subse grand jury subpoena us department justice quently unsealed company served operative antitrust division requesting documents information complaint january thecomplaint alleges defen period beginning september present pertaining dants engaged various improper transactions allegedly investigation alleged violations antitrust laws designed report false prescription drug prices federal gov blood reagents industry thecompany complied subpoena ernment order reduce companys medicaid rebate obliga november antitrust division provided notice tions thecomplaint alleges company improperly closed itsinvestigation weeks following public announce retaliated plaintiff raised allegations ment ocd received subpoena antitrust internally thecomplaint alleges variety causes action division multiple class action complaints filed thevarious federal false claims act corresponding state local cases consolidated pretrial purposes eastern statutes thecompany yet responded complaint district pennsylvania anticipates filing motion dismiss may new jersey attorney general issued sub february company received subpoena poena depuy orthopaedics inc seeking information regarding us securities exchange commission sec requesting docu financial interest clinical investigators performed clinical ments relating participation several johnson johnson studies depuy orthopaedics inc depuy spine inc depuy subsidiaries united nations iraq oil food program orthopaedics responded requests subsidiaries cooperating sec us department may company received letter united justice doj states house representatives committee oversight february company voluntarilydisclosedto thedoj government reform committee requesting information sec subsidiaries outside united states believed documents regarding april recall various infants made improper payments connection sale medical childrens liquid products mcneil consumer healthcare division devices two smallmarketcountries payments may fall mcneilppc inc mcneil consumer healthcare thecompany within jurisdiction foreign corruptpractices act fcpa produced documents information response course continuingdialogues theagencies issues requests may committee conducted public hearing potentially rising thelevel fcpa violations additional markets thereafter company received additional information requests broughtto attention theagencies company committee including requests regarding recall thecompany provided continueto provide additional certain motrin products mcneil consumer healthcare information thedoj sec cooperate agencies company produced documents information response reviews matters lawenforcement agencies number requests thecommittee held another public hearing countries alsopursuing investigations matters voluntarily september company continues cooperate disclosed company thedoj sec discussions fullywith committees ongoinginformation requests underway effort resolve thesematters iraq oil food matter referenced whether agreementcan reached whatterms isuncertain johnson johnson annual reportin addition mcneil consumer healthcare certain affiliates respectto theabove matters company includingjohnson johnson companies received grand subsidiaries vigorously contesting allegations asserted jury subpoenas united states attorneys office otherwise pursuing defenses maximize eastern district pennsylvania requesting documents broadly prospectof success thecompany subsidiaries involved relating recent recalls various products mcneil consumer matters continually evaluate strategies managing healthcare fda inspections fort washington matters appropriate pursue settlements pennsylvania lancaster pennsylvania manufacturing facilities resolutions best interest company addition government served mcneilppc inc civil thecompany also involved number patent trademark investigative demand seeking records relevantto investigation lawsuits incidental business todetermine violation false claims actthe ultimate legal andfinancial liability company companies cooperating united states attorneys office respect claims lawsuits proceedings referred responding subpoenas reasonably estimated however companys opinion thecompanies also received civil investigative demands based examination matters experience date cids multiple state attorneys general offices broadly relat discussions counsel ultimate outcome legal proceedings ing mcneil recall issues thecompanies continue produce net liabilities accrued companys balance sheet documents response cids otherwise cooperate expected material adverse effect companys finan inquiries january oregon attorney general cial position although resolutionin reportingperiod one filed civil complaint johnson johnson mcneilppc inc ormore matters could material impact mcneil healthcare llc state court alleging civil violations companys results operations cash flows period oregon unlawful trade practices act relating earlier recall mcneil otc product thedefendants intend seek dismissal restructuring civil complaint furthermore lawsuit filed september share fourth quarter company announced global holder united states district court thedistrict new restructuring initiatives designed strengthen companys posi jersey monk v johnson johnson thecomplaint seeks class tion one worlds leading global health care companies certification based upon antifraud provisions federal program allow company invest new growth platforms securities laws related mcneil manufacturing facilities ensure successful launch many new products andcontin specifically complaint alleges companies certain ued growth core businesses provide flexibility adjust individuals including officers employees failed disclose changed evolving global environment number manufacturing facilities failing maintain current duringthefiscal fourth quarter thecompany recorded good manufacturing practices cgmps result billion related pretax charges approximately price companys stock declined significantly million pretax restructuring charges expected multiple complaints seeking class action certification related require cash payments billion restructuring charges con themcneil recalls filed united states districtcourt sists severance costs million asset writeoffs mil eastern district pennsylvania northern district illi lion million related leasehold contract obligations nois central district california southern district million asset writeoffs relate inventory million ohio consumer complaints allege generallythat purchasers recorded cost products sold property plantand equipment various mcneil medicines owed monetary damages penal million intangible assets million assets ties paid premium prices defective medications million additionally part program company plans rather less expensive alternative medications complaint eliminate approximately positions approximately seeks certification nationwide class purchasers med eliminated since restructuring announced icines october judicial panel multidistrict litiga thefollowing table summarizes severance charges tion consolidated consumer complaints haviland v mcneil associated spending fiscal year ended ed pa smith v mcneilnd ill burrell v mcneilnd ill dollars millions severance degroot v mcneilnd ill michaud v mcneilnd ill nguyen restructuring charge v mcneilnd ill roberson v mcneilnd ill rivera v johnson cash outlays johnson cdcal coleman v mcneil sd ohio pretrial reserve balance january proceedings united states districtcourt eastern dis cash outlays trict pennsylvania plaintiffs filed consolidated amended civil consumer class action complaint cac naming additional parties reserve balance january andclaims january defendants currently intend file cash outlays severance expected substantiallypaid outoverthe next months motion dismiss cac motion filed march inaccordance companys plans local laws scheduled heard may additional information therestructuring relates recent years company received numerous requests segments see note froma variety united states congressional committees produce information relevant ongoingcongressional inquiries itis companys policy cooperate inquiries producingthe requested information notes consolidated financial statements report independent registered public accounting firm shareholders board directors johnson johnson control based assessed risk audits also included per formingsuch procedures considered necessary opinion accompanying consolidated balance sheets circumstances believe audits provide reasonable related consolidated statements earnings statements basis opinions equity statements cash flows present fairly material discussed note consolidated financial state respects financial position johnson johnson sub ments company changed manner accounts sidiaries company january january business combinations results operations cash flows companys internal control financial reporting three years period ended january conformity process designed provide reasonable assurance regarding accountingprinciples generally accepted united states reliability financial reporting preparation financial america also opinion company maintained statements external purposes accordance generally material respects effective internal control financial reporting accepted accountingprinciplesa companys internal control january based criteria established ininternal financial reporting includes policies procedures controlintegrated frameworkissued committee spon ipertain maintenance records reasonable detail soring organizations treadway commission coso accurately fairly reflect transactions dispositions companys management responsible financial state assets company ii provide reasonable assurance trans ments maintainingeffective internal control financial actions recorded necessary permit preparation financial reporting assessment effectiveness internal con statements accordance generally accepted accountingprin trol financial reporting included accompanying man ciples receipts expenditures company agements report internal control financial reporting made accordance authorizations management responsibility express opinions financial statements directors company iii provide reasonable assurance companys internal control financial reporting regarding prevention timely detection unauthorized acquisi based integrated audits conducted audits accor tion use disposition companys assets couldhave dance standards public company accounting material effect financial statements sight board united states thosestandards require plan inherent limitations internal control finan perform audits obtain reasonable assurance cial reporting may prevent detect misstatements also pro whether financial statements free material misstatement jections evaluation effectiveness future periods whether effective internal control financial reporting subject risk controls may becomeinadequate maintained material respects audits financial state changes conditions degree compliance ments included examining test basis evidence supporting policies procedures may deteriorate amounts disclosures financial statements assessing accounting principles used significantestimates made man agement evaluating overall financial statement presenta tion audit internal control financial reporting included obtaining understanding internal control financial report ing assessing risk material weakness exists testing new york new york evaluating design operating effectiveness internal february johnson johnson annual reportmanagements report internal control financial reporting section sarbanesoxley act manage established committee sponsoring organizations ment required assess effectiveness companys inter treadway commission coso internal controlintegrated nal control financial reporting end fiscal year framework thesecriteria areas control environment report based assessmentwhether companys risk assessment control activities information communication internal control financial reporting effective monitoring thecompanys assessment included extensive management company responsible establishing documenting evaluating testing design operating andmaintaining adequate internal control financial reporting effectiveness internal controls financial reporting companys internal control financial reporting designed based companys processes assessment provide reasonable assurance reliability companys described management concluded january financial reportingandthepreparation external financial state companys internal control financial reporting ments accordance generallyaccepted accounting principles waseffective internal controls financial reporting matter well theeffectiveness companys internal control designed inherent limitations therefore internal control financial reporting january audited financial reporting determined beeffective provide rea pricewaterhousecoopers llp independent registered public sonable assurance respectto financial statement preparation accountingfirmas stated report appears herein may prevent detect misstatements moreover projec tions evaluation effectiveness future periods subject risk controls may becomeinadequate changes conditions degree compliance policies procedures may deteriorate thecompanys management assessed effectiveness william c weldon dominic j caruso companys internal control financial reporting january chairman board directors vice president finance making thisassessment company used criteria chief executive officer chief financial officer managements report internal control financial reporting summary operations statistical data dollars millions except pershare figures sales customer us sales customer international total sales cost products sold selling marketing administrative expenses research development expense purchased inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provisionfor taxes income provisionfor taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholdersequity percent increasedecrease overpreviousyear sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholdersequity per share market price per share yearend close average shares outstanding millionsbasic diluted employees thousands also included cost materials services category includes taxes income payroll property otherbusiness taxes summary operations statistical datashareholder return performance graphs set rth el line raph mparin umulati e tal hareh lder return n thec mpan c mm n st r peri e ear ten ear endin e em er umulati et talreturn thestandard p r st index thestandard p r pharma euti al indexand thestandard p r healthcare equipmentindex raph ta le umethat e ted n e em er e em er inea h thec mpan c mm n st thestandard p r st index standard p r pharma euti al indexand thestandard p r healthcare equipmentindex thatall di idend ererein e ted year cumulative total shareholderreturn hn n hn n sp index sp pharmaceutical index sp health care equipmentindex year c r sp sp pharm sp h c equip sp index sp pharmaceuticalindex sp healthcare equipmentindex year cumulative total shareholderreturn hn n hn n sp index sp pharmaceutical index sp health care equipmentindex year c r sp sp pharm sp h c equip sp index sp pharma euti al index sphealthcareequipmentindex shareholder return performance graphs reconciliation nongaap financial measures thetables provided reconcilecertain financial disclosures letter shareholders vs vs dollars millions except pershare data change change earnings provision taxes incomeas reported purchased inprocess research development iprd gain litigation settlements net restructuring expense product liability expense depuyasrhip recall program earnings provision taxes incomeas adjusted net earningsas reported purchased inprocess research development iprd gain litigation settlements net restructuring expense product liability expense depuyasrhip recall program net earningsas adjusted diluted net earnings per shareas reported purchased inprocess research development iprd gain litigation settlements net restructuring expense product liability expense depuyasrhip recall program diluted net earnings per shareas adjusted vs vs dollars millions change change net cash flows operating activities additions property plant equipment free cash flow thecompany believes investors gain additional perspective underlying business trends results providing free cash flow measure earnings tax net earnings diluted net earnings per share excludes iprd charges special items order evaluate ongoing business operations thesenongaap financial measures considered replacements read together comparable gaap financial measures reconciliation nongaap financial measuresprincipal office investor relations contact one johnson johnson plaza louise mehrotra new brunswick new jersey vice president investor relations annual meeting annual meeting shareholders take transfer agent registrar place april hyatt regency new questions regarding stock holdings brunswick albany street new brunswick certificate replacementtransfer dividends new jersey meeting convene address changes directed shareholders cordially invited attend computershare trust company na formal notice meeting proxy statement royall street proxy sent shareholders canton corporate governance outside us copies companys annual report wwwcomputersharecom quarterly reports form q current reports form k dividend reinvestment plan securities exchange commission proxy plan allows full partial years caring see story statement annual report available dividend reinvestment additional monthly online wwwinvestorjnjcomsecfilingscfm cash investments per year company founders james wood shareholders without charge upon written johnson johnson common stock without johnson left edward mead johnson top request secretary companys brokerage commissions service charges robert wood johnson bottom principal address calling stock purchases interested advertisement circa participating plan need authoriza sigma rotating platform knee addition companys corporate tion form andor information please call depuy orthopaedics inc governance website wwwinvestorjnjcom computershare trust company na credo governancecfm shareholders view j ohnsons baby shampoo companys principles corporate outside us johnson johnson consumer governance charters audit committee products company compensation benefits committee hearing impaired c ypher sirolimuseluting coronary stent nominating corporate governance shareholders inquiries regarding cordis corporation committee policy business conduct stockrelated matters communicate directly first aid woods emergency case employees code business conduct computershare trust company na red cross catgut ethics members board directors via telecommunications device tdd executive officers copies telephone number service b andaid brand drybak adhesive bandages circa documents available shareholders outside without charge upon written request us rh immune globulin human rhogam orthoclinical diagnostics secretary companys principal address registered shareholders wish receive johnsons baby powder circa company required file exhibit electronic notice online access future e xtra strength tylenol rapid release fiscal year certifica annual reports proxy materials instead gels mcneilppc inc tions section sarbanesoxley paper copies may register online day acuvue trueye contact lenses act signed chief executive officer wwwcomputersharenacomgreen johnson johnson vision care inc chief financial officer addition rthogynol nonoxynol company required submit certification beneficial johnson johnson shareholders ortho pharmaceutical corporation signed chief executive officer shares broker bank p rocrit epoetin alfa centocor ortho new york stock exchange within days fol register online delivery materials going biotech products lp lowing annual meeting shareholders httpenrollicsdeliverycomjnj copies certifications filed previous paper used publication made years posted companys corporate j ohnson johnson web postconsumer recycled fiber forest stewardship council certified chain custody governance website future certifications company website wwwjnjcom manufactured green energy credits purchase posted promptly upon filing electricity generated renewableenergy sources online annual report wind lowimpact hydro resources wwwinvestorjnjcomannualreport common stock listed new york stock exchange company blog wwwjnjbtwcom stock symbol jnj johnson johnson history blog shareholder relations contact wwwkilmerhousecom douglas k chia facebook follow johnson johnson corporate secretary johnson johnson annual report contains many network valuable trademarks owned used twitter jnjcomm jnjstories johnson johnson family companies united states internationally distinguish jnjvideo jnjhistory products services outstanding quality youtube wwwyoutubecomjnjhealth johnson johnson corporate shareholder information